WO2021180205A1 - Pvrig结合蛋白及其医药用途 - Google Patents
Pvrig结合蛋白及其医药用途 Download PDFInfo
- Publication number
- WO2021180205A1 WO2021180205A1 PCT/CN2021/080470 CN2021080470W WO2021180205A1 WO 2021180205 A1 WO2021180205 A1 WO 2021180205A1 CN 2021080470 W CN2021080470 W CN 2021080470W WO 2021180205 A1 WO2021180205 A1 WO 2021180205A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pvrig
- seq
- antibody
- tigit
- antigen
- Prior art date
Links
- 108091008324 binding proteins Proteins 0.000 title claims description 34
- 102000014914 Carrier Proteins Human genes 0.000 title description 16
- 101001102797 Homo sapiens Transmembrane protein PVRIG Proteins 0.000 claims abstract description 291
- 102100039630 Transmembrane protein PVRIG Human genes 0.000 claims abstract description 182
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 72
- 238000000034 method Methods 0.000 claims abstract description 61
- 201000011510 cancer Diseases 0.000 claims abstract description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 230000027455 binding Effects 0.000 claims description 172
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 149
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 137
- 239000000427 antigen Substances 0.000 claims description 136
- 108091007433 antigens Proteins 0.000 claims description 135
- 102000036639 antigens Human genes 0.000 claims description 135
- 210000004027 cell Anatomy 0.000 claims description 117
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 110
- 108060003951 Immunoglobulin Proteins 0.000 claims description 70
- 102000018358 immunoglobulin Human genes 0.000 claims description 70
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 53
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 51
- 229920001184 polypeptide Polymers 0.000 claims description 50
- 108090000623 proteins and genes Proteins 0.000 claims description 44
- 230000035772 mutation Effects 0.000 claims description 41
- 102000004169 proteins and genes Human genes 0.000 claims description 38
- 239000012634 fragment Substances 0.000 claims description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 31
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 29
- 201000010099 disease Diseases 0.000 claims description 27
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 26
- 239000002157 polynucleotide Substances 0.000 claims description 26
- 108091033319 polynucleotide Proteins 0.000 claims description 26
- 102000040430 polynucleotide Human genes 0.000 claims description 26
- 210000000822 natural killer cell Anatomy 0.000 claims description 22
- 210000004602 germ cell Anatomy 0.000 claims description 18
- 230000002062 proliferating effect Effects 0.000 claims description 10
- 230000003213 activating effect Effects 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 201000005202 lung cancer Diseases 0.000 claims description 7
- 208000020816 lung neoplasm Diseases 0.000 claims description 7
- 201000001441 melanoma Diseases 0.000 claims description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 239000000969 carrier Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 230000028327 secretion Effects 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 230000001965 increasing effect Effects 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 101001037139 Homo sapiens Immunoglobulin heavy variable 3-30 Proteins 0.000 claims description 3
- 101001037153 Homo sapiens Immunoglobulin heavy variable 3-7 Proteins 0.000 claims description 3
- 102100040219 Immunoglobulin heavy variable 3-30 Human genes 0.000 claims description 3
- 102100040231 Immunoglobulin heavy variable 3-7 Human genes 0.000 claims description 3
- 210000000447 Th1 cell Anatomy 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 230000010261 cell growth Effects 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 230000014828 interferon-gamma production Effects 0.000 claims description 2
- 230000000770 proinflammatory effect Effects 0.000 claims description 2
- 102000023732 binding proteins Human genes 0.000 claims 18
- 206010061818 Disease progression Diseases 0.000 claims 1
- 230000005750 disease progression Effects 0.000 claims 1
- 229940099472 immunoglobulin a Drugs 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 abstract description 27
- 235000001014 amino acid Nutrition 0.000 description 56
- 150000001413 amino acids Chemical class 0.000 description 47
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 40
- 230000000694 effects Effects 0.000 description 38
- 235000018102 proteins Nutrition 0.000 description 36
- 238000002474 experimental method Methods 0.000 description 33
- 102000045804 human PVRIG Human genes 0.000 description 30
- 230000000903 blocking effect Effects 0.000 description 23
- 239000000203 mixture Substances 0.000 description 22
- 239000003446 ligand Substances 0.000 description 21
- 102100035488 Nectin-2 Human genes 0.000 description 19
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 19
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 19
- 101150065403 NECTIN2 gene Proteins 0.000 description 18
- 238000001514 detection method Methods 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- 239000013604 expression vector Substances 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 125000005647 linker group Chemical group 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 14
- 150000007523 nucleic acids Chemical class 0.000 description 14
- 238000007796 conventional method Methods 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 125000000539 amino acid group Chemical group 0.000 description 12
- 102000049823 human TIGIT Human genes 0.000 description 12
- 230000004048 modification Effects 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 230000003993 interaction Effects 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- -1 deoxyribose sugars Chemical class 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000006210 lotion Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 10
- 229920001223 polyethylene glycol Polymers 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 238000010494 dissociation reaction Methods 0.000 description 9
- 230000005593 dissociations Effects 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 241000282836 Camelus dromedarius Species 0.000 description 7
- 102100029740 Poliovirus receptor Human genes 0.000 description 7
- 108700008625 Reporter Genes Proteins 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 239000002773 nucleotide Chemical group 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000022534 cell killing Effects 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 241000282567 Macaca fascicularis Species 0.000 description 5
- 206010040047 Sepsis Diseases 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000003127 radioimmunoassay Methods 0.000 description 5
- 101100240346 Homo sapiens NECTIN2 gene Proteins 0.000 description 4
- 108010073807 IgG Receptors Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 108091005461 Nucleic proteins Proteins 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 102000046334 human NECTIN2 Human genes 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 3
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 3
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 3
- 230000009918 complex formation Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000012893 effector ligand Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 230000006320 pegylation Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 108010048507 poliovirus receptor Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 241000282832 Camelidae Species 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- 108010021472 Fc gamma receptor IIB Proteins 0.000 description 2
- 102000009490 IgG Receptors Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 description 2
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 201000006966 adult T-cell leukemia Diseases 0.000 description 2
- 230000009824 affinity maturation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000013074 reference sample Substances 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- 208000035657 Abasia Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 229940125557 BMS-986207 Drugs 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004053 Bacterial toxaemia Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 102100038077 CD226 antigen Human genes 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 229940125560 EOS-884448 Drugs 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical class C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 102100030708 GTPase KRas Human genes 0.000 description 1
- 241000251152 Ginglymostoma cirratum Species 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 238000001265 Jonckheere trend test Methods 0.000 description 1
- 206010069755 K-ras gene mutation Diseases 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 101100445364 Mus musculus Eomes gene Proteins 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 101150068449 PVRIG gene Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000220286 Sedum Species 0.000 description 1
- 206010053879 Sepsis syndrome Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000013222 Toxemia Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 101100445365 Xenopus laevis eomes gene Proteins 0.000 description 1
- 238000000367 ab initio method Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 108010027090 biotin-streptavidin complex Proteins 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 229920000547 conjugated polymer Polymers 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000000804 electron spin resonance spectroscopy Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 150000002243 furanoses Chemical class 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 150000002337 glycosamines Chemical group 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000012004 kinetic exclusion assay Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229920001427 mPEG Polymers 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000000716 merkel cell Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920002859 polyalkenylene Polymers 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 238000000455 protein structure prediction Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 150000003214 pyranose derivatives Chemical class 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000002702 ribosome display Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 229950007133 tiragolumab Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present disclosure relates to PVRIG binding proteins, such as anti-PVRIG antibodies and bispecific antibodies formed with anti-TIGIT antibodies, and their use as drugs for the treatment of cancer.
- Tumor immunotherapy is a hot spot in the field of tumor therapy, and tumor immunotherapy with T cells is at its core. Tumor immunotherapy is to make full use of and mobilize the killer T cells in tumor patients to kill tumors. It may be the most effective and safest way to treat tumors. Tumor immunotherapy currently has good prospects for the treatment of several different types of cancer, including disseminated metastatic tumors.
- T cells in the human body adopts a system of two signal pathways.
- a series of co-stimulatory molecules are also required to provide the second signal.
- This dual-signal pathway system plays a vital role in the balance of the immune system in the body. It strictly regulates the body's different immune responses to self and non-self antigens. If the second signal provided by the costimulatory molecule is absent, it will lead to a non-response of T cells or a sustained specific immune response, which will lead to tolerance. Therefore, the second signaling pathway plays a very critical regulatory role in the entire process of the body's immune response.
- PVRIG also known as CD112R
- CD112R is a protein expressed on the cell surface. It belongs to the B7/CD28 superfamily equivalent to TIGIT, CD96 and CD226, and plays an important role in the immune system. It contains an extracellular region, a transmembrane region, and an intracellular region. When its ligand PVRL2 (also called CD112) binds to PVRIG, it will activate the ITIM domain of PVRIG's intracellular region, making PVRIG play an immunosuppressive effect.
- PVRL2 also called CD112
- PVRIG is mainly expressed on the surface of CD4 + T cells, CD8 + T cells and NK cells.
- PVRIG and its ligand PVRL2 are highly expressed in many solid tumors, including lung cancer, breast cancer, ovarian cancer, kidney cancer, gastric cancer, endometrial cancer, head and neck cancer, etc.
- the expression of PVRIG in these cancers is highly correlated with TIGIT and PD-1. Similar to PD-1 and TIGIT, PVRIG-positive T cells will also be Eomes-positive and Tbet-negative, indicating that PVRIG is related to T cell depletion. Therefore, PVRIG may represent a new immune checkpoint in addition to PD-1 and TIGIT, and play a role of redundancy. In vitro cell experiments and mouse models have shown that knocking out or inhibiting mouse PVRIG can effectively inhibit tumor growth and coordinate with PD-1 and TIGIT inhibitors.
- TIGIT tumor infiltrating lymphocytes
- TIL tumor infiltrating lymphocytes
- Tregs Tregs that infiltrate different types of tumors.
- PVR cognate ligand PVR
- Compugen's COM701 is the world's first humanized hybridoma antibody against PVRIG that has been approved by the FDA to enter the clinic. It is currently in phase I clinical phase for the treatment of cancer. Surface Oncology also has anti-PVRIG antibody SRF-813 under development.
- Anti-TIGIT antibodies include Genentech’s tiragolumab, Ono Pharmaceutical’s BMS-986207 co-developed with BMS, Merck’s MK-7684, iTeos Therapeutics’ EOS-884448, and Arcus Biosciences’ AB-154, all of which are in clinical phase II.
- the prior art still lacks anti-PVRIG antibodies, anti-PVRIG/TIGIT bispecific antibodies with high affinity, high selectivity, and high biological activity that can inhibit cancer or tumor growth in vivo.
- the present disclosure aims to provide such antibodies by preventing Cut off the inhibitory pathway of PVRIG and/or TIGIT to activate immunity to treat cancer.
- the present disclosure provides PVRIG binding proteins, anti-PVRIG antibodies (such as VHH) and their bispecific antibodies with anti-TIGIT antibodies, and their encoding nucleic acids, vectors, host cells, pharmaceutical compositions, methods for treating cancer, and pharmaceutical applications.
- anti-PVRIG antibodies such as VHH
- bispecific antibodies with anti-TIGIT antibodies and their encoding nucleic acids, vectors, host cells, pharmaceutical compositions, methods for treating cancer, and pharmaceutical applications.
- the present disclosure provides PVRIG binding proteins or anti-PVRIG antibodies.
- the PVRIG binding protein comprises at least one immunoglobulin single variable domain, and the at least one immunoglobulin single variable domain comprises three complementarity determining regions CDR1, CDR2, and CDR3, wherein:
- CDR1 is selected from SEQ ID NO: 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64
- CDR2 is selected from SEQ ID NO: 8, 11, 14, 17, 20, 23, 26, 29, 32, 35, 38, 41, 44, 47, 50, 53, 56, 59, 62, 65
- CDR3 is selected from SEQ ID NO: 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 150, 151 Any shown amino acid sequence or amino acid sequence with 3, 2, 1 or more amino acid differences.
- SEQ ID NO: 7-21, 150, 151 are based on the Kabat coding rule
- SEQ ID NO: 22-36 is based on the Chothia coding rule
- SEQ ID NO: 37-51 is based on the IMGT coding rule
- SEQ ID NO: 52 -66 is based on AbM coding rules.
- the PVRIG binding protein comprises at least one immunoglobulin single variable domain
- the at least one immunoglobulin single variable domain comprises CDR1 in any of the sequences shown in SEQ ID NO: 2, 75-79 , CDR2, CDR3; or CDR1, CDR2, CDR3 in any of the sequences shown in SEQ ID NO: 3, 80-84; or CDR1, CDR2 in any of the sequences shown in SEQ ID NO: 4, 86-90 , CDR3; or include CDR1, CDR2, and CDR3 in any of the sequences shown in SEQ ID NO: 5, 91-95; or include CDR1, CDR2, and CDR3 in any of the sequences shown in SEQ ID NO: 6, 96-100
- the CDR1, CDR2, and CDR3 are defined according to the Kabat, IMGT, Chothia, AbM or Contact numbering system. In some specific embodiments, the CDR is determined according to the Kabat numbering system.
- the immunoglobulin single variable domain of the PVRIG binding protein contains three complementarity determining regions CDR1, CDR2, and CDR3, of which:
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 7, 8, and 9 respectively;
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 7, 8, 150, respectively;
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 10, 11, and 12, respectively;
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 10, 11, and 151, respectively;
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 13, 14, and 15, respectively;
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 16, 17, and 18, respectively; or
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 19, 20, and 21, respectively.
- the immunoglobulin single variable domain of the PVRIG binding protein contains three complementarity determining regions CDR1, CDR2, and CDR3, where:
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 22, 23, and 24, respectively;
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 25, 26, and 27, respectively;
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 28, 29, and 30, respectively;
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 31, 32, 33, respectively; or
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 34, 35, and 36, respectively.
- the immunoglobulin single variable domain of the PVRIG binding protein contains three complementarity determining regions CDR1, CDR2, and CDR3, where:
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 37, 38, and 39, respectively;
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 40, 41, and 42 respectively;
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 43, 44, and 45, respectively;
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 46, 47, and 48, respectively; or
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 49, 50, and 51, respectively.
- the immunoglobulin single variable domain of the PVRIG binding protein contains three complementarity determining regions CDR1, CDR2, and CDR3, where:
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 52, 53, 54 respectively;
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 55, 56, 57, respectively;
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 58, 59, 60, respectively;
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 61, 62, 63, respectively; or
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 64, 65, and 66, respectively.
- a PVRIG binding protein comprising an immunoglobulin single variable domain comprising CDR1, CDR2, and CDR3, wherein the immunoglobulin The amino acid sequences of CDR1, CDR2 and CDR3 of the single variable domain of the protein, respectively
- the PVRIG binding protein of the present disclosure is an antibody or an antigen-binding fragment thereof, preferably a VHH antibody, more preferably a humanized and/or affinity matured VHH antibody.
- the amino acid sequence of the immunoglobulin single variable domain of the PVRIG binding protein of the present disclosure is shown in any one of SEQ ID NO: 2-6, or has at least 80%, at least 90%, At least 95%, at least 98%, or at least 99% sequence identity.
- the PVRIG binding protein is a variant protein, which has 3, 2, 1 or more amino acid differences in CDR1 of the above-mentioned PVRIG binding protein, and/or 3, 2, 1 or more amino acids in CDR2 Differences, and/or 3, 2, 1 or more amino acid differences in CDR3.
- an anti-PVRIG antibody which comprises CDR1, CDR2, and CDR3 in the above PVRIG binding protein. It can be humanized and/or affinity matured.
- the amino acid sequence of the anti-PVRIG antibody is as shown in SEQ ID NO: 2-6, 75-84, 86-100, or has at least 80%, at least 90%, at least 95%, or at least 98%, at least 99% sequence identity.
- the anti-PVRIG single domain antibody is linked to the Fc region of human IgG1, IgG2, IgG3, IgG4, for example, it is linked to the Fc region of IgG4 with S228P, F234A, L235A, and/or K447A mutations (e.g., SEQ ID NO: 101 or 153).
- the immunoglobulin single variable domain in the PVRIG binding protein of the present disclosure is a single domain antibody (VHH), and in some specific embodiments, the VHH is humanized and/or affinity matured VHH.
- VHH single domain antibody
- the PVRIG binding protein of the present disclosure comprises an antibody.
- the PVRIG binding protein of the present disclosure is an antibody (e.g., VHH).
- the PVRIG binding protein of the present disclosure is a camelid antibody, a humanized antibody, or a fully human antibody.
- the PVRIG binding protein of the present disclosure or the immunoglobulin single variable domain therein is a camel antibody, wherein the amino acid sequence of VHH is shown in any one of SEQ ID NO: 2-6, or has at least 70% therewith. %, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% sequence identity.
- the PVRIG binding protein of the present disclosure or the immunoglobulin single variable domain therein is a humanized antibody
- the framework region of the antibody is the heavy chain framework region of a human germline template, such as IGHV3-7, specifically, IGHV3 -7*01, IGHV3-30*02.
- the amino acid sequence of the anti-PVRIG humanized antibody of the present disclosure is shown in any one of SEQ ID NO: 75-84, 86-100, or has at least 70%, at least 80%, or at least 90% therewith. , At least 95%, at least 96%, at least 97%, at least 98%, at least 99% sequence identity.
- the PVRIG binding protein of the present disclosure comprises or is a humanized antibody that comprises the heavy chain framework region of a human germline template.
- the heavy chain framework region of the human germline template is IGHV3-7*01 or IGHV3-30*02.
- the amino acid sequence of the immunoglobulin single variable domain of the humanized antibody is as shown in SEQ ID NO: 75-84 and 86-100, or has at least 90%, At least 95%, at least 98%, or at least 99% sequence identity.
- the PVRIG binding protein of the present disclosure further comprises a human immunoglobulin Fc region, such as the Fc region of human IgG1, IgG2, IgG3, and IgG4.
- the human immunoglobulin Fc region is the Fc region of human IgG4.
- the human immunoglobulin Fc region is the Fc region of human IgG1.
- the Fc region may have mutations, such as S228P, F234A, L235A, and/or K447A amino acid mutations (for example, SEQ ID NO: 101 or 153).
- the immunoglobulin single variable domain capable of specifically binding to PVRIG is connected to the immunoglobulin Fc region directly or through a linker.
- the linker may be a non-functional amino acid sequence with a length of 1-20, 1-30, 1-40, 1-50 or more amino acids and no secondary or higher structure.
- the joint may be a flexible joint, such as GS, GAP, ASGS, G 4 S, (G 4 S) 2 , (G 4 S) 3 , (G 4 S) 4 , (G 4 S) 5 , (G 4 S) 6 , YGNGT, (YGNGT) 2 , (YGNGT) 3 , (YGNGT) 4 , (YGNGT )5 , (YGNGT )6, etc.
- the Fc region of the PVRIG binding protein of the present disclosure allows the PVRIG binding protein to form a dimer molecule comprising two or four PVRIG binding domains.
- PVRIG binding proteins are also called bivalent or tetravalent PVRIG binding proteins.
- the dimer is, for example, a homodimer.
- the K D value of the combined human PVRIG is less than 1 ⁇ 10 -7 M;
- the K D value of the PVRIG binding protein or anti-PVRIG antibody binding to PVRIG of the present disclosure may be less than 1 ⁇ 10 -7 M, less than 1 ⁇ 10 -8 M, less than 1 ⁇ 10 -9 M, and less than 1 ⁇ 10 -10 M.
- the PVRIG binding protein or anti-PVRIG antibody of the present disclosure can inhibit tumor growth by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least About 80%.
- the PVRIG binding protein or anti-PVRIG antibody of the present disclosure may be monomeric, and/or PEGylated, and/or glycosylated, and/or albumin conjugated or fused, and/or Fc fused, and/or Or hydroxyethylated, and/or O-glycosylated.
- the present disclosure provides bispecific antibodies against PVRIG.
- bispecific antibodies comprising a first antigen-binding domain and a second antigen-binding domain, wherein the first antigen-binding domain specifically binds to PVRIG.
- the first antigen-binding domain of the bispecific antibody of the present disclosure specifically binds to PVRIG
- the first antigen-binding domain comprises at least one immunoglobulin single variable domain (such as VHH), and At least one immunoglobulin single variable domain (such as VHH) contains three complementarity determining regions CDR1, CDR2 and CDR3, of which:
- CDR1 is selected from SEQ ID NO: 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64
- CDR2 is selected from SEQ ID NO: 8, 11, 14, 17, 20, 23, 26, 29, 32, 35, 38, 41, 44, 47, 50, 53, 56, 59, 62, 65
- CDR3 is selected from SEQ ID NO: 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 150, 151 Any shown amino acid sequence or amino acid sequence with 3, 2, 1 or more amino acid differences.
- SEQ ID NO: 7-21 is based on Kabat coding rules
- SEQ ID NO: 22-36 is based on Chothia coding rules
- SEQ ID NO: 37-51 is based on IMGT coding rules
- SEQ ID NO: 52-66 is based on AbM coding rules.
- the first antigen-binding domain that specifically binds to PVRIG in the bispecific antibody comprises at least one immunoglobulin single variable domain, and the at least one immunoglobulin single variable domain comprises SEQ ID NO: 2.
- the first antigen-binding domain (such as VHH) that specifically binds to PVRIG includes three complementarity determining regions CDR1, CDR2, and CDR3, of which:
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 7, 8, and 9 respectively;
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 7, 8, 150, respectively;
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 10, 11, and 12, respectively;
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 10, 11, and 151, respectively;
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 13, 14, and 15, respectively;
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 16, 17, and 18, respectively; or
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 19, 20, and 21, respectively.
- the first antigen-binding domain (such as VHH) that specifically binds to PVRIG includes three complementarity determining regions CDR1, CDR2, and CDR3, of which:
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 22, 23, and 24, respectively;
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 25, 26, and 27, respectively;
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 28, 29, and 30, respectively;
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 31, 32, 33, respectively; or
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 34, 35, and 36, respectively.
- the first antigen-binding domain (such as VHH) that specifically binds to PVRIG includes three complementarity determining regions CDR1, CDR2, and CDR3, of which:
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 37, 38, and 39, respectively;
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 40, 41, and 42 respectively;
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 43, 44, and 45, respectively;
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 46, 47, and 48, respectively; or
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 49, 50, and 51, respectively.
- the first antigen-binding domain (such as VHH) that specifically binds to PVRIG includes three complementarity determining regions CDR1, CDR2, and CDR3, of which:
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 52, 53, 54 respectively;
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 55, 56, 57, respectively;
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 58, 59, 60, respectively;
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 61, 62, 63, respectively; or
- amino acid sequences of CDR1, CDR2, and CDR3 are shown in SEQ ID NOs: 64, 65, and 66, respectively.
- the first antigen-binding domain (such as VHH) of the bispecific antibody of the present disclosure comprises the amino acid sequence shown in any one of SEQ ID NO: 2-6, 75-84, 86-100, or has A sequence that is at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical.
- the first antigen binding domain is the first antibody, which is VHH;
- the second antigen binding domain is a second antibody, which includes a heavy chain (HC) and a light chain (LC);
- the VHH as the first antibody is located at the N-terminus and/or C-terminus of the heavy chain or light chain of the second antibody.
- the bispecific antibody of the present disclosure includes one second antibody and two VHH first antibodies; the second antibody includes two HCs and two LCs, and one HC of the second antibody is VH It forms an antigen-binding site with the VL of one LC, and the VH of the other HC forms an antigen-binding site with the VL of another LC.
- one of the first VHH antibodies of the bispecific antibodies of the present disclosure is located at the N-terminus of the heavy chain or light chain of the second antibody, and the other VHH first antibody is located at the heavy chain or the N-terminus of the second antibody.
- the C-terminus of the light chain is located at the N-terminus of the heavy chain or the light chain of the second antibody.
- the first antibody of each VHH in the bispecific antibody of the present disclosure is located at the N-terminus of the two heavy chains or the two light chains of the second antibody; or, the first antibody of each VHH is respectively Located at the C-terminus of the two heavy chains or two light chains of the second antibody.
- the first antibody of each VHH in the bispecific antibodies of the present disclosure is located at the N-terminus of the two heavy chains of the first antibody; or, the first antibody of each VHH is located at the first antibody.
- the first antibody of the present disclosure may be linked with 1, 2, 3, 4, 5, 6, 7, 8 VHH second antibodies, and the VHH second antibodies may be the same or different , They can all be connected to the N-terminus of the heavy chain of the first antibody, or both are connected to the C-terminus of the heavy chain of the first antibody, or both are connected to the N-terminus of the light chain of the first antibody, or both are connected to the light chain of the first antibody.
- Chain C-terminus or any combination of heavy chain N-terminus, heavy chain C-terminus, light chain N-terminus, and light chain C-terminus.
- the first antibody of the VHH in the bispecific antibody of the present disclosure is connected to the N-terminus or C-terminus of each heavy chain of the second antibody directly or through a linker.
- the linker is selected from the group consisting of: (G m S n ) x or (GGNGT) x or (YGNGT) x amino acid sequences, wherein m and n are each independently selected from an integer of 1-8 (e.g., 1, 2, 3, 4, 5, 6, 7 or 8), x is independently selected from an integer of 1-20 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20).
- the linker is an amino acid sequence represented by G 4 S, (G 4 S) 2 , (G 4 S) 3 , (G 4 S) 4 , (G 4 S) 5 , and (G 4 S) 6.
- the heavy chain of the second antibody of the bispecific antibody of the present disclosure includes a heavy chain variable region (VH) and a heavy chain constant region (CH), and the light chain includes a light chain variable region (VL) and a light chain.
- the second antibody may be a full-length antibody.
- the heavy chain of the second antibody of the bispecific antibody of the present disclosure is of the IgG isotype, such as IgG1, IgG2, IgG3, or IgG4, such as the IgG1 isotype; and/or, the second antibody The light chain is of the Kappa isotype.
- the two HCs of the second antibody of the bispecific antibody of the present disclosure comprise the same CDR and/or the two LCs comprise the same CDR. In some embodiments, the two HCs of the second antibody comprise the same VH and/or the two LCs comprise the same VL. In some specific embodiments, the two HCs of the second antibody have the same amino acid sequence and/or the two LCs have the same amino acid sequence.
- the first antibodies of the two VHHs of the bispecific antibodies of the present disclosure have the same or different amino acid sequences.
- the first antibodies of the two VHHs have the same amino acid sequence.
- the bispecific antibody of the present disclosure comprises two first polypeptide chains and two second polypeptide chains, wherein for each polypeptide chain: a) the first polypeptide chains each independently comprise the first polypeptide chain of VHH The heavy chain (HC) of the first antibody and the second antibody; and b) the second polypeptide chain each independently includes the light chain (LC) of the second antibody; wherein the VHH is connected to the N-terminus of the HC of the first antibody through a linker. / Or C terminal is connected.
- the first polypeptide chains each independently comprise the heavy chain (HC) of the second antibody; and ii) the second polypeptide chains each independently comprise the light chain (LC) of the first antibody of VHH and the second antibody ;
- the VHH is connected to the N-terminus and/or C-terminus of the LC of the second antibody directly or through a linker.
- the bispecific antibodies of the present disclosure comprise two identical first polypeptide chains and two identical second polypeptide chains.
- the second antigen binding domain of the bispecific antibody of the present disclosure is any anti-TIGIT antibody.
- the TIGIT antibodies in WO2009126688, WO2014089113, WO2015009856, WO2015143343, WO2015174439, WO2016028656, WO2016106302, WO2017053748, WO2017030823, US20160176963, US20130251720, WO2019232484, WO2019062832 are introduced in full here.
- the TIGIT antibody can be any of CPA.9.083.H4 (S241P), CPA.9.086.H4 (S241P), CHA.9.547.7.H4 (S241P), and CHA.9.547.13.H4 (S241P) (See WO2019232484).
- the second antigen binding domain of the bispecific antibody of the present disclosure is a second antibody.
- the anti-TIGIT antibody in WO2019062832 is introduced in full here as a secondary antibody.
- the second antibody is introduced in full here as a secondary antibody.
- the heavy chain variable region includes HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 115, 116, and 117, and the light chain variable region includes LCDR1, LCDR2, and HCDR2, as shown in SEQ ID NO: 118, 119, and 120, respectively.
- the heavy chain variable region includes HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 121, 122, and 123, respectively; the light chain variable region includes LCDR1, LCDR2, and HCDR2, as shown in SEQ ID NO: 124, 125, and 126, respectively. LCDR3; or
- the heavy chain variable region includes HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 127, 128, and 129, respectively; the light chain variable region includes LCDR1, LCDR2, and HCDR2, as shown in SEQ ID NO: 130, 131, and 132, respectively. LCDR3; or
- the heavy chain variable region includes HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 133, 134, and 135, respectively; the light chain variable region includes LCDR1, LCDR2, and HCDR2, as shown in SEQ ID NO: 136, 137, and 138, respectively. LCDR3; or
- the heavy chain variable region includes HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 139, 140, and 141, respectively; the light chain variable region includes LCDR1, LCDR2, and HCDR2, as shown in SEQ ID NO: 142, 143, and 144, respectively. LCDR3.
- the first antigen-binding domain or the first antibody (such as VHH) in the bispecific antibody of the present disclosure comprises CDR1, CDR2, CDR3 as shown in SEQ ID NO: 7, 8, 9, or The CDR1, CDR2, and CDR3 shown in SEQ ID NOs: 7, 8, 150;
- the second antigen-binding domain or the heavy chain variable region of the second antibody includes those shown in SEQ ID NOs: 121, 122, 123, respectively HCDR1, HCDR2, HCDR3, the light chain variable region includes LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 124, 125, and 126, respectively.
- the first antigen-binding domain or the first antibody (such as VHH) in the bispecific antibody of the present disclosure includes CDR1, CDR2, CDR3 as shown in SEQ ID NO: 10, 11, 12, or includes The CDR1, CDR2, and CDR3 shown in SEQ ID NOs: 10, 11, and 151;
- the second antigen-binding domain or the heavy chain variable region of the second antibody includes those shown in SEQ ID NOs: 121, 122, and 123, respectively HCDR1, HCDR2, HCDR3, the light chain variable region includes LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NOs: 124, 125, and 126, respectively.
- the first antibody of the VHH in the bispecific antibody of the present disclosure comprises an amino acid sequence as shown in one of SEQ ID NO: 6, 79, 81, 92, 98, 99 or has at least 70% , At least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% sequence identity;
- the second antibody comprises any one of SEQ ID NO: 145-147 VH, SEQ ID NO: VL shown in any one of SEQ ID NO: 148-149, or HC shown in SEQ ID NO: 102 and LC shown in SEQ ID NO: 103, or the same as the VH, HC or VL, LC.
- the bispecific antibodies of the present disclosure comprise:
- the first polypeptide chain is shown in SEQ ID NO: 104, and the second polypeptide chain is shown in SEQ ID NO: 103;
- the first polypeptide chain is shown in SEQ ID NO: 105, and the second polypeptide chain is shown in SEQ ID NO: 103;
- the first polypeptide chain is shown in SEQ ID NO: 102, and the second polypeptide chain is shown in SEQ ID NO: 106;
- the first polypeptide chain is shown in SEQ ID NO: 102, and the second polypeptide chain is shown in SEQ ID NO: 107;
- the Fc region of the PVRIG binding protein, anti-PVRIG antibody, and anti-TIGIT bispecific antibody of the present disclosure has mutations, including one or more amino acid mutations selected from the following:
- antibodies that compete with the PVRIG binding protein, PVRIG ⁇ TIGIT binding protein, anti-PVRIG single domain antibody, anti-PVRIG and TIGIT bispecific antibodies of the present disclosure to bind to the same epitope are provided.
- the present disclosure provides a PVRIG/TIGIT binding protein, which comprises a first antigen binding domain that specifically binds to PVRIG and a second antigen binding domain that specifically binds to TIGIT,
- the first antigen-binding domain that specifically binds to PVRIG comprises an immunoglobulin single variable domain, and the immunoglobulin single variable domain comprises:
- the CDR1, CDR2, CDR3 are defined according to the Kabat, IMGT, Chothia, AbM or Contact numbering system.
- the amino acid sequences of CDR1, CDR2, and CDR3 of the immunoglobulin single variable domain are respectively
- the first antigen-binding domain of the PVRIG/TIGIT binding protein comprises SEQ ID NO: 2-6, 75-84 and 86-100 or has at least 90%, An amino acid sequence with at least 95%, at least 98%, or at least 99% sequence identity.
- the second antigen binding domain of the PVRIG/TIGIT binding protein comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein:
- the heavy chain variable region includes the HCDR1, HCDR2, and HCDR3 shown in SEQ ID NOs: 115, 116, and 117, respectively, and the light chain variable region includes the HCDR1, HCDR2, and HCDR3 shown in SEQ ID NOs: 118, 119, and 120, respectively.
- the heavy chain variable region includes HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 121, 122, and 123, respectively, and the light chain variable region includes HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 124, 125, and 126, respectively.
- the heavy chain variable region includes the HCDR1, HCDR2, and HCDR3 shown in SEQ ID NOs: 127, 128, and 129, respectively, and the light chain variable region includes the HCDR1, HCDR2, and HCDR3 shown in SEQ ID NOs: 130, 131, and 132, respectively.
- the heavy chain variable region includes HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 133, 134, and 135, respectively, and the light chain variable region includes HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 136, 137, and 138, respectively.
- the heavy chain variable region includes HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 139, 140, and 141, respectively, and the light chain variable region includes HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NOs: 142, 143, and 144, respectively.
- the second antigen binding domain of the PVRIG/TIGIT binding protein comprises a full-length heavy chain (HC) and a full-length light chain (LC);
- the full-length heavy chain is of IgG1 or IgG4 isotype, and the full-length light chain is of Kappa isotype;
- the heavy chain sequence is shown in SEQ ID NO: 102 or has at least 90% sequence identity with it
- the light chain sequence is shown in SEQ ID NO: 103 or has at least 90% sequence identity with it sex.
- the VHH that specifically binds to the first antigen-binding domain of PVRIG is located in the heavy chain variable region or the entire heavy chain that specifically binds to the second antigen-binding domain of TIGIT.
- the VHH that specifically binds to the first antigen-binding domain of PVRIG is located at the C-terminus of the heavy chain variable region or the full-length heavy chain that specifically binds to the second antigen-binding domain of TIGIT;
- the VHH that specifically binds to the first antigen-binding domain of PVRIG is located at the N-terminus of the light chain variable region or the full-length light chain that specifically binds to the second antigen-binding domain of TIGIT; and/or
- the VHH that specifically binds to the first antigen-binding domain of PVRIG is located at the C-terminus of the light chain variable region or the full-length light chain that specifically binds to the second antigen-binding domain of TIGIT.
- the VHH that specifically binds to the first antigen-binding domain of PVRIG and the second antigen-binding domain that specifically binds to TIGIT are connected directly or through a linker;
- the linker has an amino acid sequence as shown in (G 4 S) x , wherein x is independently selected from an integer of 1-20;
- the linker is an amino acid sequence shown by (G 4 S) 2 and (G 4 S) 3.
- the PVRIG/TIGIT binding protein provided by the present disclosure comprises a first polypeptide chain and a second polypeptide chain, wherein:
- the first polypeptide chain includes the amino acid sequence shown in any one of SEQ ID NO: 108-112 and 114, and the second polypeptide chain includes the amino acid sequence shown in SEQ ID NO: 103; or
- the first polypeptide chain includes the amino acid sequence shown in SEQ ID NO: 104 or 105
- the second polypeptide chain includes the amino acid sequence shown in SEQ ID NO: 103; or
- the first polypeptide chain includes the amino acid sequence shown in SEQ ID NO: 102
- the second polypeptide chain includes the amino acid sequence shown in SEQ ID NO: 106 or 107.
- the present disclosure provides polynucleotides that encode the aforementioned PVRIG binding protein, PVRIG/TIGIT binding protein, anti-PVRIG antibody (such as VHH) or anti-PVRIG and TIGIT bispecific antibody.
- the polynucleotide may be DNA or RNA.
- a polynucleotide composition comprising:
- the first nucleic acid encodes the VH or HC including the bispecific antibody of the present disclosure against PVRIG and TIGIT; and the second nucleic acid encodes the VL or LC including the bispecific antibody of the present disclosure against PVRIG and TIGIT.
- the present disclosure provides an expression vector or expression vector composition containing the polynucleotide or polynucleotide composition as described above.
- the expression vector may be a eukaryotic expression vector, a prokaryotic expression vector, or a viral vector.
- an expression vector composition comprising:
- a first expression vector comprising the first nucleic acid in the above polynucleotide composition
- the second expression vector includes the second nucleic acid in the above polynucleotide composition.
- the present disclosure provides a host cell transformed with or containing the expression vector or expression vector composition as described above, which may be a eukaryotic cell or a prokaryotic cell.
- the host cell is a bacterium, yeast, or mammalian cell. In some specific embodiments, the host cell is Escherichia coli, Pichia pastoris, Chinese hamster ovary (CHO) cells or human embryonic kidney (HEK) 293 cells.
- the present disclosure provides a preparation method, comprising: expressing PVRIG binding protein, anti-PVRIG antibody (such as VHH), anti-PVRIG and TIGIT bispecific antibody in the host cell as described above, and extracting from the host cell Separate and recover PVRIG binding protein, anti-PVRIG antibodies (such as VHH), anti-PVRIG and TIGIT bispecific antibodies from cells.
- anti-PVRIG antibody such as VHH
- anti-PVRIG and TIGIT bispecific antibody from cells.
- the present disclosure provides a method for preparing PVRIG binding protein, PVRIG/TIGIT binding protein, or anti-PVRIG antibody or antigen binding fragment thereof, including:
- PVRIG binding protein Isolated and expressed PVRIG binding protein, PVRIG/TIGIT binding protein or anti-PVRIG antibody or antigen binding fragment thereof from the host cell.
- the present disclosure provides a composition (such as a pharmaceutical composition), which contains a therapeutically effective amount of the above-mentioned PVRIG binding protein, anti-PVRIG antibody (such as VHH), anti-PVRIG and TIGIT bispecific antibody, or PVRIG /TIGIT binding protein, and pharmaceutically acceptable excipients, dilutions or carriers.
- a composition such as a pharmaceutical composition
- the composition (such as a pharmaceutical composition) contains the PVRIG binding protein or anti-PVRIG antibody (such as VHH) of the present disclosure, and an anti-TIGIT antibody.
- the TIGIT antibody may be any anti-TIGIT antibody as described above, for example, the anti-TIGIT antibody in Table 23 and Table 24 of the present disclosure.
- the combined species may contain pharmaceutically acceptable excipients, diluents or carriers.
- the anti-TIGIT antibody contains HCDR1, HCDR2, HCDR3 shown in SEQ ID NOs: 121, 122, and 123, and the light chain variable region contains the HCDR1, HCDR2, and HCDR3 shown in SEQ ID NOs: 124, 125, 126, respectively.
- the pharmaceutical composition unit can contain 0.01 to 99% by weight of PVRIG binding protein, anti-PVRIG antibody (such as VHH), anti-PVRIG and TIGIT bispecific antibody, or pharmaceutical composition unit
- the amount of bispecific antibody containing PVRIG binding protein, anti-PVRIG antibody (such as VHH), anti-PVRIG and TIGIT in the dose is 0.1-2000mg, or 1-1000mg.
- anti-PVRIG antibodies such as VHH
- bispecific antibodies against PVRIG and TIGIT PVRIG/TIGIT binding proteins
- encoding polynucleotides PVRIG binding proteins of the present disclosure
- anti-PVRIG antibodies Such as VHH
- any one of anti-PVRIG and TIGIT bispecific antibodies, coding polynucleotides, or any combination thereof, used in methods for diagnosing, treating, and preventing diseases and preparing drugs and pharmaceutical compositions such as , Used to treat or prevent proliferative disorders (such as cancer or tumors) or delay the progress of related disorders).
- a method for treating and alleviating a condition of a subject comprising administering to the subject the PVRIG binding protein of the present disclosure, an anti-PVRIG antibody (such as VHH), an anti-PVRIG and TIGIT bispecific antibody, so Said disease is cancer.
- an anti-PVRIG antibody such as VHH
- an anti-PVRIG and TIGIT bispecific antibody so Said disease is cancer.
- a method for activating cytotoxic T cells (CTL) in a subject comprising administering to the subject the PVRIG binding protein of the present disclosure, an anti-PVRIG antibody (such as VHH), an anti-PVRIG and TIGIT dual A specific antibody, wherein the subgroup of the CTL of the subject is activated.
- an anti-PVRIG antibody such as VHH
- a method for activating NK cells in a subject comprising administering to the subject a PVRIG binding protein of the present disclosure, an anti-PVRIG antibody (such as VHH), an anti-PVRIG and TIGIT bispecific antibody, wherein The subgroup of NK cells of the subject is activated.
- an anti-PVRIG antibody such as VHH
- a method for activating ⁇ T cells in a subject comprising administering to the subject the PVRIG binding protein of the present disclosure, an anti-PVRIG antibody (such as VHH), an anti-PVRIG and TIGIT bispecific antibody, wherein The subgroup of ⁇ T cells of the subject is activated.
- an anti-PVRIG antibody such as VHH
- an anti-PVRIG and TIGIT bispecific antibody wherein The subgroup of ⁇ T cells of the subject is activated.
- a method for activating Th1 cells in a subject comprising administering to the subject a PVRIG binding protein of the present disclosure, an anti-PVRIG antibody (such as VHH), an anti-PVRIG and TIGIT bispecific antibody, wherein The subset of Th1 cells of the subject is activated.
- a PVRIG binding protein of the present disclosure an anti-PVRIG antibody (such as VHH), an anti-PVRIG and TIGIT bispecific antibody, wherein The subset of Th1 cells of the subject is activated.
- a method for activating, reducing or eliminating the cell number and/or activity of at least one of regulatory T cells (Treg) in a subject comprising administering the PVRIG of the present disclosure to the subject Binding protein, anti-PVRIG antibody (such as VHH), anti-PVRIG and TIGIT bispecific antibody.
- Reg regulatory T cells
- a method for increasing interferon- ⁇ production and/or pro-inflammatory cytokine secretion in a subject comprising administering to the subject the PVRIG binding protein, anti-PVRIG antibody (such as VHH ), bispecific antibodies against PVRIG and TIGIT.
- anti-PVRIG antibody such as VHH
- a method for inhibiting the interaction of PVRIG and PVLR2 in a subject comprising administering to the subject the PVRIG binding protein of the present disclosure, an anti-PVRIG antibody (such as VHH), an anti-PVRIG and TIGIT dual Specific antibodies.
- an anti-PVRIG antibody such as VHH
- an anti-PVRIG and TIGIT dual Specific antibodies comprising administering to the subject the PVRIG binding protein of the present disclosure, an anti-PVRIG antibody (such as VHH), an anti-PVRIG and TIGIT dual Specific antibodies.
- a method of treating a subject comprising administering to the subject or subject the PVRIG binding protein, anti-PVRIG antibody (such as VHH), anti-PVRIG and TIGIT bispecific antibody of the present disclosure.
- the condition of the subject described above is a proliferative disorder (e.g., cancer or tumor) or suffers from a proliferative disorder (e.g., cancer or tumor).
- the cancer or tumor is selected from the following or a combination thereof: prostate cancer, liver cancer (HCC), colorectal cancer, ovarian cancer, endometrial cancer, breast cancer, triple negative breast cancer, pancreatic cancer, stomach (stomach/gastric) cancer , Cervical cancer, head and neck cancer, thyroid cancer, testicular cancer, urothelial cancer, lung cancer (small cell lung cancer, non-small cell lung cancer), melanoma, non-melanoma skin cancer (squamous and basal cell carcinoma), nerve Glioma, renal cell carcinoma (RCC), lymphoma (NHL or HL), acute myelogenous leukemia (AML), T-cell acute lymphoblastic leukemia (T-ALL), diffuse large B-cell lymphoma, testicular reproduction Cell tumors
- the cancer or tumor is selected from the following cancers or a combination thereof: triple negative breast cancer, gastric cancer, lung cancer (small cell lung cancer, non-small cell lung cancer), Merck cell carcinoma, high MSI cancer, KRAS mutation tumor , Adult T-cell leukemia/lymphoma and myelodysplastic syndrome (MDS).
- the cancer or tumor is selected from the following cancers or a combination thereof: triple negative breast cancer, gastric cancer, lung cancer (small cell lung cancer, non-small cell lung cancer), Merck cell carcinoma, and high MSI cancer.
- the aforementioned subject has a condition associated with PVRIG and/or TIGIT.
- the subject’s condition includes cancers that express or do not express PVRIG and further include non-metastatic or non-invasive and invasive or metastatic cancers, in which immune cells, stromal cells, or diseased cells inhibit PVRIG expression Anti-tumor response and anti-infiltrating immune response.
- the method of the present disclosure is particularly suitable for the treatment of vascularized tumors.
- a method for treating or preventing infection or sepsis in a subject comprising administering to the subject or subject the PVRIG binding protein, anti-PVRIG antibody (such as VHH), anti-PVRIG and TIGIT's bispecific antibody.
- the infection is a pathogen infection, which is characterized by varying degrees of functional impairment of virus-specific T cell responses, such as HIV, HCV, and HBV.
- the sepsis includes severe sepsis, septic shock, systemic inflammatory response syndrome (SIRS), bacteremia, sepsis, toxemia, and sepsis syndrome.
- the above-mentioned PVRIG binding protein, PVRIG/TIGIT binding protein, anti-PVRIG antibody or antigen binding fragment, polynucleotide, or composition of the present disclosure is provided for use in treating or delaying diseases, preferably, The disease is a proliferative disease;
- the proliferative disease is cancer
- the cancer is selected from lung cancer, prostate cancer, breast cancer, head and neck cancer, esophageal cancer, stomach cancer, colon cancer, colorectal cancer, bladder cancer, cervical cancer, uterine cancer, ovarian cancer, liver cancer, melanoma , Kidney cancer, squamous cell carcinoma, blood system cancer, or any other disease or condition characterized by uncontrolled cell growth.
- a method for diagnosing a disease including:
- the tissue can be a blood sample, a solid tumor biopsy sample.
- the PVRIG binding protein or anti-PVRIG antibody can be labeled, and further, the second labeled antibody bound to the PVRIG binding protein or anti-PVRIG antibody can be contacted with the aforementioned sample.
- the PVRIG binding protein or anti-PVRIG antibody is labeled, including radioisotopes, dyes (such as with biotin-streptavidin complex), contrast agents, fluorescent compounds or molecules, and Enhancers for magnetic resonance imaging (MRI) (for example, paramagnetic ions).
- the disease or condition is cancer or tumor, infection or sepsis as described above.
- the present disclosure provides the detection use of PVRIG binding protein.
- the present disclosure provides a composition for detecting PVRIG, the composition comprising a PVRIG binding protein or an anti-PVRIG antibody.
- the present disclosure also provides methods, systems or devices for detecting PVRIG in vivo or in vitro, which include the use of PVRIG binding proteins or anti-PVRIG antibodies.
- the in vitro detection method, system or device may, for example, include (1) contacting the sample with PVRIG binding protein or anti-PVRIG antibody; (2) detecting the complex formed between the PVRIG binding protein or anti-PVRIG antibody and the sample ; And/or (3) contacting a reference sample (for example, a control sample) with the antibody; and (4) determining the degree of complex formation between the antibody and the sample by comparing with the reference sample.
- a change in complex formation in the sample or subject indicates the presence of PVRIG in the sample.
- the in vivo detection method, system or device may include: (1) administering a PVRIG binding protein or anti-PVRIG antibody to the subject; and (2) detecting the difference between the PVRIG binding protein or anti-PVRIG antibody and the subject The formation of inter-complex. Detection can include determining the location or time of formation of the complex.
- Antibodies that bind PVRIG can be directly or indirectly labeled with a detectable substance to facilitate detection of bound or unbound antibodies. Suitable detectable substances include various enzymes, prosthetic groups, fluorescent substances, luminescent substances and radioactive substances.
- the formation of complexes between PVRIG binding protein or anti-PVRIG antibody and PVRIG can be detected by measuring or visualizing antibodies that bind or do not bind to PVRIG.
- Conventional detection assays can be used, for example, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) or tissue immunohistochemistry.
- the sample is analyzed for the presence of PVRIG by a competitive immunoassay that uses a standard labeled with a detectable substance and an unlabeled PVRIG binding protein or anti-PVRIG antibody.
- the living body sample to be detected or measured may be tissue cells, blood, plasma, serum, pancreatic juice, urine, feces, tissue fluid or culture fluid.
- the PVRIG binding protein or anti-PVRIG antibody of the present disclosure may be labeled with a fluorophore and a chromophore.
- kits which includes a PVRIG binding protein or an anti-PVRIG antibody, and may also include diagnostic instructions.
- the kit may also contain at least one additional reagent, such as a marker or additional diagnostic agent.
- the antibody can be formulated as a pharmaceutical composition.
- the PVRIG antibodies, anti-PVRIG and TIGIT double antibodies provided in the embodiments of the present disclosure have high specificity and high affinity for PVRIG and/or TIGIT; the immunogenicity of the humanized antibodies is greatly reduced, while completely retaining excellent in vivo and in vitro activities ; It has good metabolic kinetic characteristics of rats and human body; has long half-life, high bioavailability; has good long-term stability, no obvious abnormal chemical modification, no obvious aggregation under high concentration, high purity and heat Stability; has a good effect of enhancing the activity of T cells and NK cells, and inhibiting the occurrence and development of tumors.
- Figure 1 shows the results of the PVRIG reporter cell activity test of the anti-PVRIG antibody.
- Figure 2 shows the test results of anti-PVRIG antibody activating NK cells in the NK cell killing experiment.
- Figure 3 shows the test results of the activity of the anti-PVRIG antibody to activate T cells in the MLR experiment.
- Figures 4A-4B show the results of detection of humanized anti-PVRIG antibody activity in PVRIG reporter gene cells.
- Figures 5A-5B are the detection results of the humanized anti-PVRIG antibody activating NK cells in the NK cell killing experiment.
- Figures 6A-6E respectively show the binding activity of the humanized anti-PVRIG/TIGIT bispecific antibody to human PVRIG recombinant protein, human PVRIG overexpressing cells, cynomolgus monkey PVRIG recombinant protein, and cynomolgus monkey PVRIG overexpressing cells, and The detection result of the activity of blocking the combination of human PVRIG and human PVRL2.
- Figures 7A-7E respectively show the binding activity of the humanized anti-PVRIG/TIGIT bispecific antibody to human TIGIT recombinant protein, human TIGIT overexpressing cells, cynomolgus TIGIT recombinant protein, and cynomolgus TIGIT overexpressing cells, and The detection result of the activity of blocking the combination of human TIGIT and human PVR.
- Figure 8 shows the results of the activity detection of humanized anti-PVRIG/TIGIT bispecific antibodies in the MLR experiment to activate T cells.
- Figures 9A-9B respectively show the effect of anti-PVRIG/TIGIT bispecific antibody on mouse body weight and tumor volume in a mouse subcutaneous xenograft model of human melanoma A375 mixed with human PBMC.
- Figures 10A-10B respectively show the effect of anti-PVRIG/TIGIT bispecific antibody on the body weight and tumor volume of the mouse subcutaneous transplanted tumor model of human melanoma A375 mixed with human PBMC.
- PVRIG or “PVRIG protein” or “PVRIG polypeptide” may optionally include any such protein or variants, conjugates or fragments thereof, including but not limited to known or wild-type PVRIG as described herein, And any naturally occurring splice variants, amino acid variants or isoforms, and especially the soluble extracellular domain (ECD) fragment of PVRIG.
- ECD extracellular domain
- PVRIG binding protein means any protein capable of specifically binding PVRIG or any molecule containing the protein.
- the PVRIG binding protein may include an antibody against PVRIG as defined in the present disclosure, an antigen binding fragment thereof, or a conjugate thereof.
- PVRIG binding proteins also encompass immunoglobulin superfamily antibodies (IgSF) or CDR grafted molecules.
- the "PVRIG binding protein” of the present disclosure may comprise at least one immunoglobulin single variable domain (such as VHH) that binds to PVRIG.
- a "PVRIG binding protein” may comprise 2, 3, 4, or more PVRIG-binding immunoglobulin single variable domains (such as VHH).
- the PVRIG binding protein of the present disclosure may also include linkers and/or parts with effector functions, such as half-life extension parts (such as immunoglobulin single variable domains that bind serum albumin). Domain), and/or fusion partner (such as serum albumin) and/or conjugated polymer (such as PEG) and/or Fc region.
- the "PVRIG binding protein" of the present disclosure also encompasses bi/multispecific antibodies, which contain immunoglobulins that bind to different antigens (such as a first antibody that binds to a first antigen (such as PVRIG) and a second antibody that binds to a second antigen).
- the second antibody to the antigen (such as TIGIT) optionally includes a third antibody that binds to a third antigen, and further optionally includes a fourth antibody that binds to the fourth antigen.
- TIGIT or "TIGIT protein” or “TIGIT polypeptide” may optionally include any such protein or variants, conjugates or fragments thereof, including but not limited to known or wild-type TIGIT as described herein, And any naturally occurring splice variants, amino acid variants or isoforms.
- the complete TIGIT sequence can be found at GenBank accession number AAI01289.1.
- Binds to PVRIG refers to the ability to interact with PVRIG or its epitope, and the PVRIG or its epitope may be of human origin.
- Binds to TIGIT refers to the ability to interact with TIGIT or its epitope, and the TIGIT or its epitope may be of human origin.
- Antigen-binding site refers to a discrete three-dimensional site on an antigen that is recognized by the antibody or antigen-binding fragment of the present disclosure.
- Antibody or “immunoglobulin” broadly encompasses traditional antibodies (antibodies with a four-peptide chain structure composed of two identical heavy chains and two identical light chains connected by interchain disulfide bonds), as well as antigens Binding active Fab, Fv, sFv, F(ab')2, linear antibody, single chain antibody, scFv, sdAb, sdFv, nanobody, peptide antibody peptibody, domain antibody (heavy chain (VH) antibody, light chain ( VL) antibody) and multispecific antibodies (bispecific antibody, diabody, triabody and tetrabody, tandem two-scFv, tandem three-scFv), therefore, the term "antibody” used in the present disclosure includes full-length antibodies, single The chain and any part, domain or fragment with antigen binding activity and the multispecific antibody (including but not limited to antigen binding domain or Fragments, such as VHH domains or VH/VL domains, respectively).
- immunoglobulins are usually a tetrapeptide chain structure composed of two identical heavy chains and two identical light chains connected by interchain disulfide bonds.
- the amino acid composition and sequence of the constant region of the heavy chain are different, so their antigenicity is also different.
- immunoglobulins can be divided into five categories, or isotypes of immunoglobulins, namely IgM, IgD, IgG, IgA, and IgE.
- the corresponding heavy chains are ⁇ chain, ⁇ chain, and ⁇ chain. , ⁇ chain, and ⁇ chain.
- the same type of Ig can be divided into different subclasses according to the amino acid composition of the hinge region and the number and position of heavy chain disulfide bonds.
- IgG can be divided into IgG1, IgG2, IgG3, and IgG4.
- the light chain is divided into a kappa chain or a lambda chain by the difference of the constant region.
- Each of the five types of Ig can have a ⁇ (kappa) chain or a ⁇ (lambda) chain.
- the antibodies of the present disclosure specifically or substantially specifically bind to PVRIG and/or TIGIT.
- the "antibody” of the present disclosure includes but is not limited to: (i) Fab fragments composed of VL, VH, CL and CH1 domains; (ii) Fd fragments composed of VH and CH1 domains; (iii) F(ab' ) 2 fragment, a bivalent fragment containing two linked Fab fragments; (vii) single-chain Fv molecule (scFv), in which the VH domain and the VL domain are connected by a peptide linker, which allows The two domains combine to form an antigen binding site; (Bird et al., 1988, "Science” 242: 423-426; Huston et al., 1988, "Proc. Natl. Acad.
- the antibodies of the present disclosure generally use the Kabat numbering system.
- the EU numbering in Kabat is also generally used for constant domains and/or Fc domains.
- the antibodies of the present disclosure may be polyclonal, monoclonal, heterologous, allogeneic, syngeneic, or modified forms thereof, and monoclonal antibodies are particularly suitable for use in various embodiments.
- the antibodies of the present disclosure are recombinant antibodies.
- "recombinant” generally refers to products such as cells or nucleic acids, proteins, or vectors, meaning that the cells, nucleic acids, proteins, or vectors have been modified by introducing heterologous nucleic acids or proteins or altering natural nucleic acids or proteins, or The cells are derived from cells so modified.
- recombinant cells express genes that are not present in the natural (non-recombinant) cell form or express natural genes that are originally abnormally expressed, underexpressed, or not expressed at all.
- Monoclonal antibody and “monoclonal antibody composition” refer to a population of antibody molecules containing only one species of antigen binding site capable of immunoreacting with a specific epitope, while “polyclonal antibody” and “polyclonal antibody A “composition” refers to a population of antibody molecules containing multiple species of antigen binding sites capable of interacting with a specific antigen. Monoclonal antibody compositions typically exhibit a single binding affinity for the specific antigen with which they are immunoreactive.
- Antigen refers to a molecule used to immunize immunocompetent vertebrates, to generate antibodies that recognize the antigen, or to screen expression libraries (e.g., phage, yeast, or ribosome display libraries, among others).
- antigens are defined more broadly and are generally expected to include target molecules specifically recognized by antibodies, and therefore include a part or mimic of molecules used in the immunization process for antibody production or library screening for selection of antibodies Things.
- Sequence (for example, in terms such as “immunoglobulin sequence”, “antibody sequence”, “single variable domain sequence”, “VHH sequence” or “protein sequence”) is generally understood to include both related amino acid sequences , Also includes the nucleic acid sequence or nucleotide sequence encoding the sequence, unless the disclosure requires further limited explanation.
- Polynucleotide or “nucleic acid” refers to a chain of nucleotides of any length, including DNA and RNA. Nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases and/or their analogs, or any substrate that can be incorporated into the chain by DNA or RNA polymerase. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and their analogs. If present, modifications to the nucleotide structure can be imparted before or after chain assembly.
- Polynucleotides may also contain similar forms of ribose or deoxyribose sugars generally known in the art, including, for example, 2'-O-methyl-, 2'-O-allyl, 2'-fluoro- or 2'- Azido-ribose, carbocyclic sugar analogs, ⁇ - or ⁇ -anomeric sugars, epimeric sugars (such as arabinose, xylose or lyxose, pyranose, furanose, sedum heptulose) ), acyclic analogs and abasic nucleoside analogs such as methyl riboside.
- ribose or deoxyribose sugars generally known in the art, including, for example, 2'-O-methyl-, 2'-O-allyl, 2'-fluoro- or 2'- Azido-ribose, carbocyclic sugar analogs, ⁇ - or ⁇ -anomeric sugars, epimeric sugars
- “Homology” or “identity” refers to the sequence similarity between two polynucleotide sequences or between two polypeptides.
- the positions in the two comparison sequences are occupied by the same base or amino acid monomer subunit, for example, if each position of the two DNA molecules is occupied by adenine, then the molecules are homologous at that position .
- the percent homology between two sequences is a function of the number of matching or homologous positions shared by the two sequences divided by the number of positions compared ⁇ 100%. For example, in the optimal sequence alignment, if there are 6 matches or homology in 10 positions in the two sequences, then the two sequences are 60% homologous. Generally speaking, the comparison is made when two sequences are aligned to obtain the greatest percentage of homology.
- domain of a polypeptide or protein refers to a folded protein structure that can maintain its tertiary structure independently of the rest of the protein. Generally speaking, a domain is responsible for a single functional property of a protein, and in many cases can be added, removed, or transferred to other proteins without losing the rest of the protein and/or the function of the domain.
- Immunoglobulin domain refers to a spherical region of an antibody chain (for example, a chain of an antibody with a conventional tetrapeptide chain structure or a chain of a heavy chain antibody), or refers to a polypeptide consisting essentially of such a spherical region.
- the immunoglobulin domain is characterized in that it maintains the immunoglobulin folding characteristics of the antibody molecule, and it consists of a 2-layer sandwich of about 7 anti-parallel ⁇ -sheet strands arranged in two ⁇ -sheets, optionally stabilized by conservative disulfide bonds. .
- Immunoglobulin variable domains are basically referred to in the art and hereinafter as “framework region 1" or “FR1”, “framework region 2" or “FR2”, “framework region 3” or “FR3”, respectively.
- an immunoglobulin domain consisting of four “framework regions” of "framework region 4" or “FR4", wherein the framework region is referred to as “complementarity determining region 1" or “CDR1” in the art and hereinafter, respectively.
- the three “complementarity determining regions” or “CDRs” of “complementarity determining region 2" or “CDR2” and “complementarity determining region 3" or “CDR3” are spaced apart.
- an immunoglobulin variable domain can be expressed as follows: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
- the immunoglobulin variable domains have antigen-binding sites that give them specificity for antigens.
- Antibody framework (FR) refers to a part of a variable domain that serves as a scaffold for the antigen binding loop (CDR) of the variable domain.
- CDR the deterministic description of CDR and the identification of residues containing the binding site of the antibody can be completed by resolving the structure of the antibody and/or resolving the structure of the antibody-ligand complex. This can be achieved by any of various techniques known to those skilled in the art, such as X-ray crystallography. A variety of analysis methods can be used to identify CDRs, including but not limited to Kabat numbering system, Chothia numbering system, AbM numbering system, IMGT numbering system, contact definition, conformational definition.
- the Kabat numbering system is a standard for numbering residues in antibodies and is commonly used to identify CDR regions (see, for example, Johnson & Wu, 2000, Nucleic Acids Res., 28:214-8).
- the Chothia numbering system is similar to the Kabat numbering system, but the Chothia numbering system takes into account the location of certain structural loop regions. (See, for example, Chothia et al., 1986, J. Mol. Biol., 196:901-17; Chothia et al., 1989, Nature, 342:877-83).
- the AbM numbering system uses a computer program integration suite produced by Oxford Molecular Group for modeling antibody structures (see, for example, Martin et al., 1989, Proc Natl Acad Sci (USA), 86: 9268-9272; "AbMTM, A Computer Program for Modeling Variable Regions of Antibodies, "Oxford, UK; Oxford Molecular, Ltd).
- the AbM numbering system uses a combination of knowledge databases and ab initio methods to model the tertiary structure of antibodies from basic sequences (see Samudrala et al., 1999, in PROTEINS, Structure, Function and Genetics Suppl., 3:194-198, "Ab Initio Protein Structure Prediction Using a Combined Hierarchical Approach).
- the contact definition is based on the analysis of available complex crystal structures (see, for example, MacCallum et al., 1996, J. Mol. Biol., 5:732-45).
- the position of the CDRs can be identified as residues that make enthalpy contributions to antigen binding (see, for example, Makabe et al., 2008, Journal of Biological Chemistry, 283:1156-1166).
- other CDR boundary definitions may not strictly follow one of the above methods, but still overlap with at least a part of Kabat CDR, although they can be shortened or lengthened according to specific residues or residue groups that do not significantly affect the prediction of antigen binding or experimental results. .
- CDR may refer to a CDR defined by any method (including a combination of methods) known in the art.
- the methods used herein can utilize CDRs defined according to any of these methods.
- the CDR can be defined according to any of Kabat, Chothia, extended, AbM, IMGT, contact, and/or conformational definitions.
- Immunoglobulin single variable domain is usually used to mean that it can be used without interacting with other variable domains (for example, when there is no requirement between the VH and VL domains of a conventional four-chain monoclonal antibody).
- an immunoglobulin variable domain (which can be a heavy chain or a light chain domain, including a VH, VHH, or VL domain) that forms a functional antigen binding site.
- immunoglobulin single variable domains include Nanobodies (including VHH, humanized VHH, and/or camelized VH, such as camelized human VH), IgNAR, domains, as VH domains or derived from VH Domain (single domain) antibodies (such as dAbs TM ) and (single domain) antibodies that are VL domains or derived from VL domains (such as dAbs TM ).
- Immunoglobulin single variable domains based on and/or derived from heavy chain variable domains are generally preferred.
- a specific example of an immunoglobulin single variable domain is a "VHH domain” (or simply "VHH") as defined below.
- VHH domain also known as heavy chain single domain antibody, VHH, VHH antibody fragment, VHH antibody, nanobody, is an antigen-binding immunoglobulin called "heavy chain antibody” (ie, "antibody lacking light chain”)
- the variable domains of proteins Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, Hamers R.: “Naturally occurring antibodies devoid of light chains”; Nature363, 446-448( 1993)).
- the term “VHH domain” is used to compare the variable domain with the heavy chain variable domain (which is referred to as "VH domain” in the present disclosure) and light chain variable domains present in conventional tetrapeptide chain structure antibodies.
- variable domain (which is referred to as the "VL domain" in this disclosure) distinguishes it.
- the VHH domain specifically binds to the epitope without the need for other antigen-binding domains (this is in contrast to the VH or VL domain in conventional tetrapeptide chain antibodies, in which case the epitope is recognized by the VL domain and the VH domain together) .
- the VHH domain is a small, stable and efficient antigen recognition unit formed by a single immunoglobulin domain.
- VHH domain includes, but is not limited to, natural antibodies produced by camelid animals, and can also be humanized antibodies produced by camelid animals, or obtained through phage display technology screening.
- the total number of amino acid residues in each CDR may be different, and may not correspond to the total number of amino acid residues indicated by Kabat numbering (ie one according to Kabat numbering). Or multiple positions may be unoccupied in the actual sequence, or the actual sequence may contain more amino acid residues than the number allowed by Kabat numbering). This means that in general, the numbering according to Kabat may or may not correspond to the actual numbering of amino acid residues in the actual sequence.
- Other numbering systems or coding rules include Chothia, IMGT, and AbM.
- the total number of amino acid residues in the VHH domain will usually be in the range of 110 to 120, often between 112 and 115. However, it should be noted that smaller and longer sequences may also be suitable for the purposes described in this disclosure.
- VHH domain (alone or as part of a larger polypeptide) offers many significant advantages over the use of conventional VH and VL domains, scFv or conventional antibody fragments (e.g. Fab- or F(ab')2-fragments):
- VHH domain can be expressed by a single gene and does not require post-translational folding or modification
- -VHH domain can be easily transformed into a multivalent and multispecific format
- -VHH domain is highly soluble and has no tendency to aggregate
- VHH domain is highly stable to heat, pH, proteases and other denaturants or conditions, and therefore can be prepared, stored or transported without using refrigeration equipment, thereby saving cost, time and environment;
- -VHH domain is relatively small compared with conventional tetrapeptide chain structure antibody and its antigen-binding fragment (approximately 15kDa or 1/10 of the size of conventional IgG), so compared to conventional tetrapeptide chain structure antibody and its antigen-binding fragment , Shows higher tissue permeability and can be administered at higher doses;
- -VHH domain can show so-called cavity binding properties (especially due to its extended CDR3 loop compared with conventional VH domain), so that it can reach targets and epitopes that are inaccessible to conventional tetrapeptide chain structure antibodies and antigen-binding fragments thereof.
- Fc variant or “variant Fc” means a protein containing amino acid modifications in the Fc domain.
- the Fc variants of the present disclosure are defined according to the amino acid modifications constituting them.
- S228P or 228P is an Fc variant with a proline substitution at position 228 relative to the parent Fc polypeptide, where the numbering is based on the EU index.
- the identity of the WT amino acid may not be specified, in this case the aforementioned variant is called 228P.
- humanization examples include the VHH domain derived from Camelidae by replacing the amino acid sequence of the original VHH sequence with one or more amino acid residues present at the corresponding position in the VH domain of a human conventional tetrapeptide chain structure antibody “Humanization” (also referred to as “sequence optimization” in the present disclosure. In addition to humanization, “sequence optimization” can also cover one or more amino acid residues that provide improved properties of VHH Mutations make other modifications to the sequence, such as removing potential post-translational modification sites).
- the humanized VHH domain may contain one or more fully human framework region sequences, and in some embodiments, may contain the human framework region sequence of IGHV3.
- humanization includes transplanting mouse CDR sequences into human antibody variable region frameworks, that is, antibodies produced from different types of human germline antibody framework sequences. It can overcome the strong variable antibody response induced by the chimeric antibody due to the large amount of mouse protein components.
- Humanization methods such as protein surface amino acid humanization (resurfacing) and antibody humanization universal framework grafting (CDR grafting to a universal framework), that is, CDR “grafting” to other "stents” (including but not limited to human stents or Non-immunoglobulin scaffold). Stents and techniques suitable for the CDR grafting are known in the art.
- the germline DNA sequences of the human heavy chain and light chain variable region genes can be found in the "VBase" human germline sequence database (available on the Internet www.mrccpe.com.ac.uk/vbase), as well as in Kabat, EA, etc. People, 1991 Sequences of Proteins of Immunological Interest, found in the 5th edition.
- the humanized antibodies of the present disclosure also include humanized antibodies that are further subjected to affinity maturation of CDRs by phage display.
- the human antibody variable region framework sequence can be subjected to minimal reverse mutations or back mutations to maintain activity.
- Affinity matured antibodies have one or more changes in one or more CDRs that result in an increase in affinity for the antigen compared to their respective parent antibodies.
- Affinity matured antibodies can be prepared, for example, by methods known in the art as described below: Marks et al., 1992, Biotechnology 10: 779-783 or Barbas et al., 1994, Proc. Nat. Acad. Sci, USA 91: 3809-3813.; Shier et al., 1995, Gene 169: 147-155; Yelton et al., 1995, Immunol.155: 1994-2004; Jackson et al., 1995, J. Immunol.154(7): 3310-9; and Hawkins et al., 1992, J. MoI. Biol. 226(3): 889896; KS Johnson and RE Hawkins, "Affinity maturation of antibodies using phage display", Oxford University Press 1996.
- the antibodies of the present disclosure will be such as to Biacore or KinExA assay measured Fortibio or preferably 10-7 to 10-10 moles / liter (M), more preferably from 10-8 to 10-10 mol / l, and even more preferably 10 -9 to 10 -10 or lower dissociation constant (KD), and/or at least 10 -7 M, preferably at least 10 -8 M, more preferably at least 10 -9 M, more preferably at least 10 -10 M
- the association constant (KA) binds to the antigen to be bound (ie PVRIG). Any KD value greater than 10 -4 M is generally regarded as indicative of non-specific binding.
- the specific binding of an antigen binding protein to an antigen or epitope can be determined in any suitable manner known, including, for example, the surface plasmon resonance (SPR) assay, Scatchard assay, and/or competitive binding assay described in this disclosure (for example, radioimmunoassay (RIA), enzyme immunoassay (EIA) and sandwich competition assay.
- SPR surface plasmon resonance
- RIA radioimmunoassay
- EIA enzyme immunoassay
- sandwich competition assay sandwich competition assay.
- Epitope or “antigenic determinant” used interchangeably refers to any epitope on the antigen to which the paratope of an antibody binds.
- Antigenic determinants usually contain chemically active surface groups of molecules, such as amino acids or sugar side chains, and usually have specific three-dimensional structural characteristics and specific charge characteristics.
- an epitope usually includes at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 consecutive or non-contiguous amino acids in a unique spatial conformation, which can be "linear "Epitope” or "Conformational” epitope.
- a linear epitope all interaction points between a protein and an interacting molecule (for example, an antibody) exist linearly along the protein's primary amino acid sequence.
- Specific binding and “selective binding” refer to the binding of an antibody to an epitope on a predetermined antigen.
- a predetermined antigen Generally, when recombinant human PVRIG, TIGIT or its epitope is used as an analyte and an antibody is used as a ligand, when measured by surface plasmon resonance (SPR) technology in the instrument, the antibody is approximately lower than 10 -7 M or even more.
- the small equilibrium dissociation constant (K D ) binds to the predetermined antigen or its epitope, and its binding affinity to the predetermined antigen or its epitope is that of the predetermined antigen (or its epitope) or closely related antigens.
- the binding affinity of foreign non-specific antigens such as BSA, etc.
- Antibody that recognizes antigen can be used interchangeably with “antibody that specifically binds” herein.
- Binding affinity is used herein as a measure of the strength of a non-covalent interaction between two molecules (eg, an antibody or part thereof and an antigen), and is used to describe a monovalent interaction (intrinsic activity).
- the binding affinity between two molecules can be quantified by determining the dissociation constant (K D ).
- K D can be determined by measuring the kinetics of complex formation and dissociation using, for example, a surface plasmon resonance (SPR) method (Biacore).
- SPR surface plasmon resonance
- the rate constants corresponding to the association and dissociation of the monovalent complex are called the association rate constant ka (or kon) and the dissociation rate constant kd (or koff), respectively.
- the value of the dissociation constant can be directly determined by a well-known method (see Caceci et al., 1984, Byte 9:340-362; Wong & Lohman, 1993, PNAS 90: 5428-5432).
- Other standard assays for assessing the ability of antibodies to bind to target antigens include, for example, ELISA, Western blot, RIA, and flow cytometry analysis, as well as other assays exemplified elsewhere herein.
- the specificity of the interaction can be determined and compared by determining and comparing the K D value of the target interaction (for example, the specific interaction between the antibody and the antigen) and the non-target interaction (for example, a control antibody that is not known to bind PVRIG). K D value is evaluated.
- the anti-PVRIG antibody of the present disclosure can bind to its target with at least 2-fold, 10-fold, 50-fold, 100-fold, 200-fold, 500-fold greater affinity than it binds to another non-PVRIG molecule. Times, 1,000 times, or 10,000 times, this is not a restrictive definition.
- conservative modifications apply to amino acid and nucleotide sequences.
- conservative modification refers to the mutual substitution of those nucleic acids that encode the same or substantially the same amino acid sequence, or in the case where the nucleotide does not encode the amino acid sequence, it refers to the substantially same nucleotide sequence .
- conservative modification means that other amino acids with similar characteristics (such as charge, side chain size, hydrophobicity/hydrophilicity, main chain conformation and rigidity, etc.) replace amino acids in the protein, so that frequent changes can be made without changing The biological activity of the protein.
- amino acid mutations include amino acid substitutions, deletions, insertions, modifications and any combination thereof to realize the final construct so that the final construct possesses the desired characteristics, such as enhanced stability and increased activity.
- Amino acid sequence deletions and insertions include amino and/or carboxy terminal deletions and amino acid insertions.
- Preferred amino acid mutations are amino acid substitutions.
- non-conservative amino acid substitutions can be made, that is, one amino acid can be replaced with another amino acid having a different structure and/or chemical properties.
- Preferred amino acid substitutions include the substitution of hydrophilic amino acids for hydrophobic amino acids.
- Amino acid substitutions include non-naturally-occurring amino acids or naturally-occurring amino acid derivatives of 20 standard amino acids (e.g. 4-hydroxyproline, 3-methylhistidine, ornithine, homoserine, 5-hydroxylysine Amino acid) substitution.
- Amino acid mutations can be generated using genetic or chemical methods known in the art, including methods such as site-directed mutagenesis, PCR, gene synthesis, and chemical modification. Amino acid mutations can occur in the CDR, FR or Fc region of the antibody.
- mutations can be introduced into the wild-type Fc sequence of the antibody of the present disclosure to change Fc-mediated related activities, and the mutations include but are not limited to: a). Changes in Fc-mediated CDC activity Mutations; b). Mutations that change Fc-mediated ADCC activity; or c). Mutations that change FcRn-mediated half-life in vivo (see Leonard G Presta, Current Opinion in Immunology 2008, 20: 460-470; Esohe E. Idusogie et al., J Immunol 2000, 164: 4178-4184; RAPHAEL A. CLYNES et al., Nature Medicine, 2000, Volume 6, Number 4: 443-446; Paul R.
- Hinton et al., J Immunol, 2006, 176: 346-356 includes: modifying the hinge region of CH1 so that the number of cysteine residues in the hinge region is changed, for example, increased or decreased (see US 5,677,425, which is incorporated in its entirety here).
- mutations that enhance binding to Fc ⁇ RIIIa to cause enhanced ADCC
- mutations that weaken binding to Fc ⁇ RIIb such as 236A, 239D, 239E, 332E, 332D, 239D/332E, 267D, 267E, 328F, 267E/328F , 236A/332E, 239D/332E/330Y, 239D, 332E/330L, 299T and 297N (see US11/124,620, US6,737,056, which are incorporated in full here).
- Carry out Fc modification to increase its biological half-life for example, one or more of the following mutations can be introduced: T252L, T254S, T256F (see US 6,277,375); in order to increase the biological half-life, the antibody can be changed in the CH1 or CL region to contain The rescue receptor binding epitope obtained from the two loops of the CH2 domain of the Fc region of IgG (see US5,869,046, US6,121,022); additional mutations used to increase the serum half-life, including 428L, 434A, 434S and 428L/ 434S (see US 8,883,973, US 6,737,056, US 7,371,826, which are incorporated in their entirety here).
- the Fc region is changed by replacing at least one amino acid residue, thereby changing the effector function of the antibody.
- one or more amino acids selected from amino acid residues 234, 235, 236, 237, 297, 318, 320, and 322 can be changed.
- the effector ligand with altered affinity may be, for example, the Fc receptor or the C1 component of complement (see US 5,624,821, US 5,648,260, which are incorporated in their entirety here).
- the Fc region is modified by modifying one or more amino acids at the following positions to improve the antibody's ability to mediate antibody-dependent cellular cytotoxicity (ADCC) and/or increase the antibody's affinity for Fc ⁇ receptors: 238, 239, 248, 249 , 252, 254, 255, 256, 258, 265, 267, 268, 269, 270, 272, 276, 278, 280, 283, 285, 286, 289, 290, 292, 293, 294, 295, 296, 298 , 301, 303, 305, 307, 309, 312, 315, 320, 322, 324, 326, 327, 329, 330, 331, 333, 334, 335, 337, 338, 340, 360, 373, 376, 378 , 382, 388, 389,
- mutations such as M252Y/S254T/T256E or M428L/N434S improve the binding to FcRn and increase the circulating half-life of the antibody (see Chan CA and Carter PJ (2010) “Nature Rev Immunol” 10:301 -316).
- Modifications of the antibodies of the present disclosure include pegylation (PEGylation) or the addition of other water-soluble moieties, for example in order to enhance the half-life.
- PEGylation refers to the attachment of at least one PEG molecule to another molecule, such as a therapeutic protein.
- PEG is a linear or branched polyether attached to a hydroxyl group at one end, and has the following general structure: HO-(CH 2 CH 2 O) n -CH 2 CH 2 -OH.
- PEG can be activated by preparing some or two derivatives of PEG with functional groups at the ends.
- the common approach for PEG conjugation of proteins is to activate PEG with a functional group suitable for the reaction with lysine and the N-terminal amino acid group.
- the common reactive group involved in conjugation is the alpha or epsilon amino group of lysine.
- the reaction of the PEGylated linker with the protein can lead to the attachment of the PEG moiety mainly at the following positions: the alpha amino group on the N-terminus of the protein, the epsilon amino group on the side chain of the lysine residue, or the histidine residue Imidazolyl on the side chain. Since most recombinant proteins have a single ⁇ and many ⁇ amino groups and imidazole groups, many positional isomers can be produced according to the chemical properties of the linking group.
- the engineered antibodies or antigen-binding fragments of the present disclosure can be prepared and purified by conventional methods.
- the cDNA sequences encoding the heavy and light chains can be cloned and recombined into an expression vector.
- the recombinant immunoglobulin expression vector can be stably transfected into CHO cells.
- Mammalian expression systems can lead to glycosylation of antibodies, especially at the highly conserved N-terminus of the Fc region.
- Stable clones are obtained by expressing antibodies that specifically bind to human antigens. Positive clones are expanded in the serum-free medium of the bioreactor to produce antibodies.
- the antibody-secreted culture medium can be purified and collected by conventional techniques.
- the antibody can be filtered and concentrated by conventional methods. Soluble mixtures and polymers can also be removed by conventional methods, such as molecular sieves and ion exchange.
- the resulting product needs to be frozen immediately, such as -70°C, or lyophilized
- administering when applied to animals, humans, experimental subjects, cells, tissues, organs or biological fluids refer to exogenous drugs, therapeutic agents, diagnostic agents or compositions and animals , Human, subject, cell, tissue, organ or biological fluid contact, such as treatment, pharmacokinetics, diagnosis, research and experimental methods.
- the treatment of cells includes contact of reagents with cells, and contact of reagents with fluids, where the fluids are in contact with cells.
- administering”, “administration” and “treatment” also mean the treatment of, for example, cells by reagents, diagnostics, binding compositions, or by another cell in vitro and ex vivo. When applied to human, veterinary or research subjects, it refers to treatment, preventive or preventive measures, research and diagnostic applications.
- Treatment means administering an internal or external therapeutic agent to a subject, such as containing any one of the antibodies of the present disclosure or a pharmaceutical composition thereof as a therapeutic agent, the subject has, is suspected of having, or is prone to There are one or more proliferative diseases or their symptoms, and the therapeutic agent is known to have a therapeutic effect on these symptoms.
- the therapeutic agent is administered in the subject or population to be treated in an amount effective to alleviate one or more symptoms of the disease, whether by inducing the regression of such symptoms or inhibiting the development of such symptoms to any clinically measurable extent.
- the amount of the therapeutic agent effective to alleviate the symptoms of any particular disease can vary depending on a variety of factors, such as the subject’s disease state, age and weight, and the amount of the drug that produces the desired therapeutic effect in the subject. ability. Through any clinical testing methods commonly used by doctors or other professional health care professionals to evaluate the severity or progression of the symptoms, it can be evaluated whether the symptoms of the disease have been alleviated.
- the embodiments of the present disclosure may be ineffective in alleviating the symptoms of the target disease in a subject, according to any statistical test methods known in the art such as Student's t test, chi-square test, and basis Mann and Whitney's U test, Kruskal-Wallis test (H test), Jonckheere-Terpstra test, and Wilcoxon test determined that it should reduce the symptoms of the target disease in a statistically significant number of subjects.
- any statistical test methods known in the art such as Student's t test, chi-square test, and basis Mann and Whitney's U test, Kruskal-Wallis test (H test), Jonckheere-Terpstra test, and Wilcoxon test determined that it should reduce the symptoms of the target disease in a statistically significant number of subjects.
- an “effective amount” includes an amount sufficient to ameliorate or prevent the symptoms or conditions of the medical condition.
- An effective amount also means an amount sufficient to allow or facilitate diagnosis.
- the effective amount for a subject can vary depending on factors such as the condition to be treated, the general health of the subject, the method of administration and dosage, and the severity of side effects.
- the effective amount can be the maximum dose or dosing schedule that avoids significant side effects or toxic effects.
- the subject of the present disclosure may be an animal or a human subject.
- “Host cell” includes individual cells or cell cultures, which may be or have been recipients of vectors for incorporation of polynucleotide inserts.
- a host cell includes the progeny of a single host cell, and due to natural, accidental or deliberate mutations, the progeny may not necessarily be exactly the same as the original parent cell (in morphology or genomic DNA complement).
- Host cells include cells transfected and/or transformed in vivo with polynucleotides of the present disclosure.
- Cell Cell line
- “cell culture” are used interchangeably, and all such names include their progeny. It should also be understood that due to deliberate or unintentional mutations, all offspring cannot be exactly the same in terms of DNA content. Including mutant progeny with the same function or biological activity as screened in the original transformed cell.
- Vector means a construct capable of being delivered in a host cell and in some embodiments expressing one or more genes or sequences of interest.
- examples of vectors include, but are not limited to, viral vectors, naked DNA or RNA expression vectors, plasmids, cosmids or phage vectors, DNA or RNA expression vectors combined with cationic condensing agents, DNA or RNA expression vectors encapsulated in liposomes , And certain eukaryotic cells such as producer cells.
- “Pharmaceutical composition” means a mixture containing one or more antibodies or antigen-binding fragments or physiologically/pharmaceutically acceptable salts or prodrugs and other chemical components of the antibodies or antigen-binding fragments described herein, as well as other components such as physiological/pharmacological Medicinal carriers and excipients.
- the purpose of the pharmaceutical composition is to promote the administration to the organism, which is beneficial to the absorption of the active ingredient and thus the biological activity.
- “Pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” includes any material that, when combined with an active ingredient, allows the ingredient to retain biological activity and does not react with the subject's immune system. Examples include, but are not limited to, any standard pharmaceutical carrier, such as phosphate buffered saline solution, water, emulsions such as oil/water emulsions, and various types of wetting agents.
- the diluent for aerosol or parenteral administration is phosphate buffered saline (PBS) or physiological (0.9%) saline.
- PBS phosphate buffered saline
- Compositions containing such carriers are formulated by well-known conventional methods (see, for example, Remington's Pharmaceutical Sciences, 18th edition, A. Gennaro, editor, Mack Publishing Co., Easton, PA, 1990; and R Remington, The Science and Practice of Pharmacy 20th Edition Mack Publishing, 2000).
- the "PVRIG binding protein” or “PVRIG antibody” of the present disclosure may include one or more effector molecules in a conjugation manner, for example.
- the "effector molecule” includes, for example, anti-tumor agents, drugs, toxins, biologically active proteins (such as enzymes), other antibodies or antibody fragments, synthetic or naturally occurring polymers, nucleic acids and fragments thereof (such as DNA, RNA and fragments thereof). ), radionuclides, in particular radioiodides, radioisotopes, chelated metals, nanoparticles and reporter groups such as fluorescent compounds or compounds detectable by NMR or ESR spectroscopy.
- the effector molecule when it is a polymer, it can usually be a synthetic or naturally occurring polymer, such as an optionally substituted linear or branched polyalkylene, polyalkenylene or polyoxyalkylene polymer or branched Polysaccharides or unbranched polysaccharides, such as homo- or hetero-polysaccharides.
- Specific optional substituents that may be present on the aforementioned synthetic polymers include one or more hydroxy, methyl or methoxy groups.
- Specific examples of synthetic polymers include optionally substituted linear or branched poly(ethylene glycol), poly(propylene glycol), poly(vinyl alcohol) or derivatives thereof, particularly optionally substituted poly(ethylene two Alcohol) such as methoxy poly(ethylene glycol) or its derivatives.
- polymers include lactose, amylose, dextran, glycogen or derivatives thereof.
- the polymer is albumin or a fragment thereof, such as human serum albumin or a fragment thereof.
- the method of conjugating the polymer to the PVRIG binding protein or PVRIG antibody can be achieved by conventional methods.
- His-tagged human PVRIG (h-PVRIG-his) recombinant protein, mouse IgG2a Fc-tagged human PVRIG (h-PVRIG-mIgG2a Fc) recombinant protein, human IgG1 Fc-tagged mouse PVRIG (m- PVRIG-hIgG1 Fc) is a purified commercial protein reagent purchased from Acrobiosystems, and its sequence is shown in Table 1.
- cyno-PVRIG-his The sequence of the cyno-PVRIG (cyno-PVRIG-his) recombinant protein with his tag is as follows:
- the recombinant protein was expressed by transient transfection in HEK293 cells by conventional methods, and the supernatant was collected and purified by Ni-NTA. After testing, cyno-PVRIG-his was obtained.
- Anti-human PVRIG monoclonal single domain antibodies are produced by immunizing camels.
- the immune antigen is human PVRIG recombinant protein (h-PVRIG-his) with his tag.
- Emulsification with Freund's adjuvant Sigma, Lot No.: F5881/F5506): First use Freund's complete adjuvant (CFA) CFA, and other booster immunizations with Freund's incomplete adjuvant (IFA).
- CFA Complete adjuvant
- IFA immunofluorization time
- the single-domain antibody variable region gene was amplified by PCR and cloned into a phage vector to build a phage library of anti-human PVRIG single-domain antibody.
- the phage library was diluted and blocked with BSA, incubated with magnetic beads Dynabeads (M-280, invitrogen), and the phage after the negative sieve incubation was collected.
- the Dynabeads were coated and blocked with biotin-labeled human PVRIG with his tag, the phage suspension collected after the negative sieve was incubated with the Dynabeads, and the phage was eluted with trypsin. After 3 rounds of screening, 400 clones from the 3rd round of screening were selected for sequencing.
- the heavy chain sequences of 5 single domain antibodies are shown in Table 2, and the CDRs with different coding rules are shown in Table 3.
- the heavy chain variable regions of the five antibodies in Example 2 were connected to the human IgG4 heavy chain Fc region to form a full-length anti-PVRIG antibody.
- the Fc region of the heavy chain includes the hinge region with S228P, F234A, L235A, and K447A mutations (Eu nomenclature system).
- the anti-PVRIG antibody CPA.7.021 shown in WO2016134333 was screened from an antibody phage library, and its subtype is IgG1, which can bind well to human PVRIG, but does not bind to cynomolgus monkey PVRIG.
- the heavy chain and light chain variable regions of CPA.7.021 were respectively connected with the human IgG4 heavy chain constant region (with S228P, F234A, L235A, K447A mutations) and the human Kappa light chain constant region to construct the positive antibody Tab5.
- the above sequence was synthesized, digested with BamHI and XhoI, and inserted into the pcDNA3.1 expression vector (Life Technologies Cat. No. V790-20) through the BamHI/XhoI restriction site.
- the expression vector and the transfection reagent PEI (Polysciences, Inc. Cat. No. 23966) were transfected into HEK293 cells (Life Technologies Cat. No. 11625019) at a ratio of 1:2, and incubated in a CO 2 incubator 4- 5 days. After the expressed antibody is recovered by centrifugation, the antibody is purified according to the conventional method, and the target antibody is obtained after detection.
- ELISA experiments were used to detect the binding properties of anti-PVRIG antibodies.
- the PVRIG recombinant protein with his tag is directly coated. After the antibody is added, the activity of the antibody binding to the antigen is detected by adding the secondary antibody (HRP-conjugated anti-Fc antibody) and the HRP substrate TMB.
- Human, cynomolgus or mouse PVRIG protein was coated with 96-well microtiter plate, 100 ⁇ L per well at a concentration of 1 ⁇ g/mL, and incubated overnight at 4°C. Wash the lotion three times, 250 ⁇ L per well. Shake for 10 seconds each time to ensure adequate cleaning. Add 300 ⁇ L/well blocking solution (PBS+0.05% Tween20+1% BSA) and incubate at room temperature for 1 hour. Wash the lotion three times, 250 ⁇ L per well. Shake for 10 seconds each time to ensure adequate cleaning. Add 100 ⁇ L of anti-PVRIG antibody to be tested diluted with diluent to each well. Incubate at 37°C for 1 hour. Wash the lotion three times, 250 ⁇ L per well.
- Flow cytometry was used to detect the binding properties of the anti-PVRIG antibody. Construct a cell line that overexpresses human or cynomolgus PVRIG. After the antibody is added, the activity of the antibody binding to the antigen is detected by adding a secondary antibody.
- the expression plasmid with human or cynomolgus monkey PVRIG gene sequence was transfected into HEK293 cells, and overexpression and stable transfection monoclonal cell lines were obtained by antibiotic selection and infinite dilution method.
- a 96-well plate was seeded with 2 ⁇ 10 5 overexpression cells per well. Centrifuge at 300g for 5 minutes, remove the supernatant, add 100 ⁇ L of the antibody to be tested, and incubate at 4°C for 1 hour.
- the anti-PVRIG antibody screened out was tested to block the binding ability of human PVRIG and its ligand human PVRL2.
- the specific method is to coat the human PVRIG recombinant protein (h-PVRIG-mIgG2a Fc) with mouse IgG2a Fc tag on a 96-well microtiter plate, add anti-PVRIG antibody to fully bind and occupy the epitope, and then add the his tag PVRL2 (PV2-H52E2, AcroBiosystem), by detecting the his tag, calculates the binding amount of PVRIG and PVRL2, and calculates the IC 50 value of the anti-PVRIG antibody blocking the active site of PVRIG.
- h-PVRIG-mIgG2a Fc protein was coated on a 96-well microtiter plate, 100 ⁇ L per well at a concentration of 1 ⁇ g/mL, and incubated overnight at 4°C. Wash the lotion three times, 250 ⁇ L per well. Shake for 10 seconds each time to ensure adequate cleaning. Add 300 ⁇ L/well blocking solution and incubate at room temperature for 1 hour. Wash the lotion three times, 250 ⁇ L per well. Shake for 10 seconds each time to ensure adequate cleaning. Add 50 ⁇ L of diluted anti-PVRIG antibody to be tested and 50 ⁇ L of his-labeled ligand PVRL2 to each well, and incubate at 37°C for 1 hour. Wash the lotion three times, 250 ⁇ L per well.
- the Protein A biosensor (Fortebio, #18-5010) was immersed in 200 ⁇ L of KB buffer (PBS, pH 7.4, 0.02% tween-20, 0.1% BSA) for 60 seconds, and then wetted. Then, use KB buffer to dilute the anti-PVRIG antibody to 10 ⁇ g/mL, place the sensor in 200 ⁇ L of this solution, and stop when the reading reaches 1.2 nm. Soak the sensor in KB buffer for 100 seconds to elute excess antibody.
- the human PVRIG with his tag was diluted 2-fold with KB buffer to between 64nM-4nM. Place the sensor in the solution and bind for 300 seconds. Dissociate the sensor in KB buffer for 600 seconds. Using dynamic 1:1 binding, the affinity of anti-PVRIG antibody and human PVRIG is shown in Table 8.
- plvx-OS8 (G418 resistant) plasmid, transfect 293F cells, select G418, use flow cytometry to detect the expression of OS8 in cloned cells and also detect the activation of OS8 on Jurkat cells, select the clone with moderate activation degree to obtain 293F -OS8 cell line; construct plvx-PVRL2 plasmid, use it to infect 293F-OS8 cells, use flow cytometry to screen out the clone with the highest expression of PVRL2, thereby obtaining 293F-OS8-PVRL2 cell line.
- plvx-NFAT-Luc Hygromycin resistant
- plvx-NFAT-Luc Hygromycin resistant
- infect Jurkat E6.1 cells add Hygromycin to screen out resistant clones
- use OKT3 to stimulate clones
- screen out clones with medium Luciferase signal Obtain the Jurkat-NFAT-Luc cell line
- construct the plvx-PVRIG Puromycin resistance
- package it into a lentivirus infect Jurkat-NFAT-Luc cells, screen out the clone with the highest expression of PVRIG by flow cytometry, and obtain Jurkat -NFAT-Luc-PVRIG cell line.
- PVRIG is expressed on NK cells, while PVRL2 is expressed on many tumor cells (including K562 cells).
- Anti-PVRIG antibodies can block the binding of PVRL2 and PVRIG to relieve the inhibitory effect of tumor cells on NK cell activity.
- NK92 cell line NK cells of human malignant non-Hodgkin's lymphoma patients
- lotion including RPMI 1640, 5% FBS, 10ng/mL IL-2
- NK92 cells NK cells of human malignant non-Hodgkin's lymphoma patients
- lotion including RPMI 1640, 5% FBS, 10ng/mL IL-2
- IL-2 resuspend to 2 ⁇ 10 6
- the density of pieces/mL Add 50 ⁇ L (1 ⁇ 10 5 in total) NK92 cells to each well in a 96-well plate.
- 50 ⁇ L of 20nM or 100nM antibody to be tested, and incubate at 37°C for 30 minutes. Wash twice with lotion and resuspend to a density of 2 ⁇ 10 5 cells/mL.
- control groups which are a sample containing only culture medium (control group one), a sample containing only NK92 cells (control group two), and 150 ⁇ L of a sample containing only K562 cells (control group three), and perform the same operation.
- Killing activity (%) ⁇ [(R–BG)-(T-BG)-(E–BG)]/[(TL-BGL)–(T-BG)] ⁇ 100
- R is the fluorescence value after adding AAF-Glo
- BG is the fluorescence value of the control group 1 when AAF-Glo is added
- E is the fluorescence value of the control group 2 when AAF-Glo is added
- T is the control group 3 when AAF-Glo is added.
- the fluorescence value of Glo is the fluorescence value of the control group 3 after adding the lysis solution
- BGL is the fluorescence value of the control group after adding the lysis solution repeatedly.
- PVRIG is expressed on T cells, while PVRL2 is expressed on dendritic cells (DC cells).
- Anti-PVRIG antibodies can block the binding of PVRL2 and PVRIG, relieve the inhibitory effect of dendritic cells on T cells, and activate T cells.
- PBMCs were isolated from the peripheral blood of the first individual, and the cells were cultured in RPMI 1640 medium containing 10% FBS at 50ng/mL GM-CSF (Peprotech, 300-03-100UG) and 50ng/mL IL- 4 (Peprotech, 200-04-100UG) add cytokine to the final concentration, add fresh medium containing cytokine every 2-3 days; after 6 days of culture, add 1 ⁇ g/mL LPS (Sigma, L2880-25MG) and incubate for 24 hours , Collect the DC cells obtained by differentiation and maturation.
- GM-CSF 50ng/mL GM-CSF
- IL- 4 50ng/mL IL- 4
- PBMC peripheral blood-derived second, using EasySep human CD3 + T cell isolation kit (Stemcell, 17952) CD3 + T cells isolated therefrom. Adjust the density of CD3 + T cells and DC cells so that 1 ⁇ 10 5 CD3 + T cells and 2 ⁇ 10 4 DC cells are added to each well. Add the antibody to be tested, incubate at 37°C for 120h, take the supernatant, and detect the IFN ⁇ content in the supernatant with an ELISA kit (R&D, DY202).
- Stem EasySep human CD3 + T cell isolation kit
- the heavy chain variable region sequence was compared with the antibody GermLine database to obtain a race with high homology Department template.
- Replace the framework region of the camel single domain antibody with the heavy chain framework region of the human germline template retain the CDR (according to the Kabat numbering system), and combine it with the Fc region of human IgG (IgG4Fc with S228P, F234A, L235A, and K447A mutations). ) Reorganization.
- antibodies 20H1-20H5 include CDR1 as shown in TDCMG (SEQ ID NO: 7), CDR2 as shown in HIDSDGIPRYVDSVKG (SEQ ID NO: 8), and CDR2 as shown in GFKFDEDYCAPND (SEQ ID NO: 150) CDR3.
- antibody 30H1-30H5 contains CDR1 as shown in GDCMG (SEQ ID NO: 10), CDR2 as shown in TIDNAGRIKYADSVKG (SEQ ID NO: 11), and CDR3 as shown in GWTFGGQCSPAD (SEQ ID NO: 151) .
- the above-mentioned humanized antibody heavy chain variable region is connected to the human IgG4 heavy chain Fc region to form a full-length anti-PVRIG antibody.
- the Fc region of the heavy chain includes the hinge region with S228P, F234A, L235A, and K447A mutations.
- the antibody is expressed and purified according to conventional methods, and the target antibody is obtained after detection.
- Example 8 the activity of the humanized anti-PVRIG antibody in the reporter gene cell was detected.
- the experimental results are shown in Figure 4A-4B and Table 19.
- the antibodies listed in the table all have the ability to activate Jurkat cells.
- Example 15 Experiment on the killing ability of activated NK cells of humanized anti-PVRIG antibody
- Example 9 the ability of humanized anti-PVRIG antibody to activate NK cells was tested.
- the experimental results are shown in Figure 5A-5B and Table 20-21.
- the results show that the humanized anti-PVRIG antibodies of the present disclosure have obvious ability to activate NK cells and promote the killing of NK cells on the target cell K562.
- the anti-PVRIG single domain antibody 151 was connected to the N of the heavy or light chain of the anti-TIGIT antibody 1708 through the GGGGSGGGGS (SEQ ID NO: 152) linker. Terminal or C terminal connected.
- Anti-TIGIT antibody 1708 adopts human IgG4 subtype and carries a mutation of S228P (Eu nomenclature system).
- the sequence of the anti-TIGIT antibody 1708 and the bispecific antibody formed with 151 is shown in Table 22 below.
- the sequence information of anti-TIGIT antibodies is shown in Table 23-24.
- the full text of the TIGIT antibody in WO2019062832A is hereby introduced.
- Antibody number Expression amount (mg/L) SEC purity (%) 1708-151-1 140 97.6 1708-151-2 108 95.7 1708-151-3 160 94.7 1708-151-4 158 96.2
- Example 5 and Example 6 the experiment was carried out, and the results are shown in Table 26.
- the results showed that the binding of bispecific antibodies with different configurations to human PVRIG recombinant protein and over-expressing human PVRIG cells, as well as the blocking of PVRL2 binding to PVRIG, are basically the same and no difference.
- Example 5 and Example 6 the corresponding receptors and ligands were replaced by human TIGIT and human PVR
- the experiment was performed, and the results are shown in Table 27.
- the results showed that the binding of bispecific antibodies and anti-TIGIT antibodies with different configurations to human TIGIT recombinant protein and over-expressing human TIGIT cells, as well as the blocking of TIGIT binding to its ligand PVR, are basically the same and no difference.
- the connection mode of the anti-PVRIG antibody 151 has little effect on the binding of the anti-TIGIT antibody to TIGIT.
- the antibody was transiently transfected, expressed and purified according to conventional methods, and the target double antibody was obtained after identification.
- the humanized anti-PVRIG/TIGIT bispecific antibody was tested for binding to human and cyno TIGIT, and blocking the binding of human TIGIT to ligand, wherein the PVRIG protein was replaced with TIGIT , And replace PVRL2 with PVR.
- the results are shown in Table 30 and Figures 7A-7E. The results showed that each double antibody can bind to human and cynomolgus TIGIT and block TIGIT from binding to PVR.
- Biacore was used to detect the affinities of humanized bispecific antibodies with human PVRIG, cynomolgus PVRIG, and human TIGIT.
- the humanized bispecific antibody was captured on the Protein A biosensor chip (GE lifesciences, 29127557) of the Biacore instrument (Biacore X100, GE), and then flowed through a series of human PVRIG antigen (AcroBiosystem , PVG-H52H4), Cynomolgus PVRIG antigen (SEQ ID NO:1), or human TIGIT antigen (AcroBiosystem, TIT-H52H3).
- Biacore instrument (Biacore X100, GE) was used to detect the reaction signal in real time to obtain the binding and dissociation curves.
- the data obtained from the experiment was fitted with BiacoreX100 evaluation software2.0GE software with a (1:1) Binding model, and the affinity value was obtained, as shown in Table 31.
- Example 20 Mixed lymphocyte reaction (MLR) experiment of humanized anti-PVRIG/TIGIT bispecific antibody
- the ability of the humanized anti-PVRIG/TIGIT bispecific antibody to activate T cells was tested.
- the experimental results are shown in Figure 8 and Table 32.
- the results show that the humanized anti-PVRIG/TIGIT bispecific antibody 1708-151H8 has obvious ability to activate T cells and promote the secretion of IFN ⁇ by T cells.
- the bispecific antibody is more active than the anti-PVRIG antibody 151H8 alone and the anti-TIGIT antibody 1708 alone.
- Example 21 Evaluation of anti-tumor effect of anti-PVRIG/TIGIT bispecific antibody in a mouse subcutaneous xenograft model of human melanoma A375 mixed with human PBMC
- NCG mice female, 4-8 weeks old, weighing about 18-22 g, purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd. All NCG mice were cultured under the conditions of SPF animal room IVC constant temperature and pressure system.
- A375 cells were cultured in DMEM medium containing 10% fetal bovine serum (FBS). A375 cells in the exponential growth phase were collected, and HBSS was resuspended to a suitable concentration for subcutaneous tumor inoculation in NCG mice. The A375 cells used for co-cultivation need to be treated with Mitomycin C for 2 hours, and then washed three times with PBS. Take normal human peripheral blood, separate human PBMC by density gradient centrifugation, and count. Then, PBMC was resuspended to a concentration of 3 ⁇ 10 6 cells/mL with RPMI1640 medium (containing IL2 and 10% FBS) and co-cultured with A375 cells treated with Mitomycin C.
- FBS fetal bovine serum
- mice After 6 days of co-cultivation, PBMCs were collected, and freshly digested A375 cells were collected at the same time. Each mouse was inoculated: 5 ⁇ 10 5 PBMCs, 4 ⁇ 10 6 A375 cells; inoculation volume: 0.2 mL/mouse (containing 50% Matrigel); inoculated subcutaneously on the right side of female NCG mice. The mice were administered in groups randomly according to their body weight. The detailed administration method, dosage and route of administration are shown in Table 34. The day of group administration is day 0. Since the molecular weights of the anti-PVRIG antibody and the anti-TIGIT antibody are different, this dosage ensures that the anti-PVRIG antibody and the anti-TIGIT antibody have the same initial molar concentration.
- N Number of animals used; i.p.: intraperitoneal injection; Q2D: once every two days; Dosing volume: Adjust the dosing volume (0.1mL/10g) according to the weight of the tumor-bearing mice.)
- mice weight and tumor volume were measured twice a week.
- the experimental results are shown in Tables 35-36 and Figures 9A-9B, respectively.
- mice were administered in groups randomly according to their body weight.
- the detailed administration method, dosage and route of administration are shown in Table 37.
- the group administration day is the 0th day.
- N Number of animals used; i.p.: intraperitoneal injection; Q2D: once every two days; Dosing volume: Adjust the dosing volume (0.1mL/10g) according to the weight of the tumor-bearing mice.)
- mice weight and tumor volume were measured twice a week.
- the experimental results are shown in Tables 38-39 and Figures 10A-10B, respectively.
- the 1708-30H2IgG4 and 1708-151H7IgG4 double antibody groups can effectively inhibit tumor growth at low doses, which is significantly different from the control group (see Figure 10A and Figure 10B).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
名称 | 氨基酸序列起止 | Genbank登录号 |
h-PVRIG-his | Thr41-Asp171 | Q6DKI7-1 |
h-PVRIG-mIgG2a Fc | Thr41-Asp171 | Q6DKI7-1 |
m-PVRIG-hIgG1 Fc | Ser35-Asp165 | A0A1B0GS01-1 |
抗体编号 | ELISA IC 50(nM) |
20 | 1.18 |
30 | 1.11 |
38 | 0.93 |
39 | 0.76 |
151 | 0.37 |
Tab5 | 1.16 |
IgG4 | 无阻断 |
抗体编号 | Kon(1/Ms) | Koff(1/s) | KD(M) |
20 | 3.43E+05 | 8.07E-05 | 2.36E-10 |
30 | 2.84E+05 | 2.05E-04 | 7.23E-10 |
38 | 1.32E+05 | 2.87E-04 | 2.17E-09 |
39 | 2.42E+05 | 1.69E-04 | 6.96E-10 |
151 | 2.61E+05 | 5.22E-05 | 2.00E-10 |
Tab5 | 7.37E+05 | 1.61E-05 | 2.19E-10 |
抗体株编号 | PVRIG报告基因细胞活性实验EC 50(nM) |
20 | 0.04 |
30 | 0.06 |
38 | 0.20 |
39 | 0.06 |
151 | 0.04 |
Tab5 | 0.74 |
IgG4 | 无结合 |
抗体编号 | Kon(1/Ms) | Koff(1/s) | KD(M) |
20H5 | 1.93E+05 | 1.35E-05 | 6.98E-11 |
30H2 | 1.69E+05 | 3.25E-04 | 1.92E-09 |
30H3 | 1.48E+05 | 3.58E-04 | 2.41E-09 |
39H1 | 2.64E+05 | 8.65E-04 | 3.28E-09 |
39H2 | 1.80E+05 | 1.24E-04 | 6.92E-10 |
39H4 | 1.89E+05 | 9.11E-05 | 4.82E-10 |
151H7 | 1.57E+05 | 1.88E-04 | 1.20E-09 |
抗体编号 | 表达量(mg/L) | SEC纯度(%) |
1708-151-1 | 140 | 97.6 |
1708-151-2 | 108 | 95.7 |
1708-151-3 | 160 | 94.7 |
1708-151-4 | 158 | 96.2 |
Claims (21)
- PVRIG结合蛋白,其包含至少一个免疫球蛋白单一可变结构域,所述免疫球蛋白单一可变结构域包含:SEQ ID NO:3、80-84任一所示序列中的CDR1、CDR2和CDR3;或SEQ ID NO:2、75-79任一所示序列中的CDR1、CDR2和CDR3;或SEQ ID NO:4、86-90任一所示序列中的CDR1、CDR2和CDR3;或SEQ ID NO:5、91-95任一所示序列中的CDR1、CDR2和CDR3;或SEQ ID NO:6、96-100任一所示序列中的CDR1、CDR2和CDR3;所述CDR1、CDR2和CDR3是根据Kabat、IMGT、Chothia、AbM或Contact编号系统定义的;优选地,根据Kabat编号系统,所述免疫球蛋白单一可变结构域的CDR1、CDR2和CDR3的氨基酸序列分别如SEQ ID NO:10、11和12或151所示;或如SEQ ID NO:7、8和9或150所示;或如SEQ ID NO:13、14和15所示;或如SEQ ID NO:16、17和18所示;或如SEQ ID NO:19、20和21所示。
- 如权利要求1所述的PVRIG结合蛋白,其中所述PVRIG结合蛋白的免疫球蛋白单一可变结构域为VHH,优选为人源化的和/或经亲合力成熟的VHH;更优选地,所述人源化的和/或经亲合力成熟的VHH包含人种系模板的重链框架区IGHV3-7*01或IGHV3-30*02。
- 如权利要求1或2所述的PVRIG结合蛋白,其中所述免疫球蛋白单一可变结构域的氨基酸序列分别如SEQ ID NO:3、80-84中任一所示;或SEQ ID NO:2、75-79中任一所示;或SEQ ID NO:4、86-90中任一所示;或SEQ ID NO:5、91-95中任一所示;或SEQ ID NO:6、96-100中任一所示;或与前述序列任一具有至少80%、至少90%、至少95%、至少98%或至少99%的序列同一性。
- 如权利要求1-3中任一项所述的PVRIG结合蛋白,其还包含人免疫球蛋白Fc区;优选地,所述Fc区是人IgG1或IgG4的Fc区;更优选地,所述人IgG4的Fc区具有S228P、F234A、L235A和/或K447A突变。
- PVRIG/TIGIT结合蛋白,其包含特异性结合PVRIG的第一抗原结合结构域和特异性结合TIGIT的第二抗原结合结构域,所述特异性结合PVRIG的第一抗原结合结构域包含至少一个免疫球蛋白单一可变结构域,所述免疫球蛋白单一可变结构域包含:SEQ ID NO:3、80-84任一所示序列中的CDR1、CDR2和CDR3;或SEQ ID NO:2、75-79任一所示序列中的CDR1、CDR2和CDR3;或SEQ ID NO:4、86-90任一所示序列中的CDR1、CDR2和CDR3;或SEQ ID NO:5、91-95任一所示序列中的CDR1、CDR2和CDR3;或SEQ ID NO:6、96-100任一所示序列中的CDR1、CDR2和CDR3;所述CDR1、CDR2、CDR3是根据Kabat、IMGT、Chothia、AbM或Contact编号系统定义的;优选地,根据Kabat编号系统,所述免疫球蛋白单一可变结构域的CDR1、CDR2和CDR3的氨基酸序列分别如SEQ ID NO:10、11和12或151所示;或如SEQ ID NO:7、8和9或150所示;或如SEQ ID NO:13、14和15所示;或如SEQ ID NO:16、17和18所示;或如SEQ ID NO:19、20和21所示。
- 如权利要求5所述的PVRIG/TIGIT结合蛋白,其中所述第一抗原结合结构域中的免疫球蛋白单一可变结构域的氨基酸序列分别如SEQ ID NO:3、80-84中任一所示;或SEQ ID NO:2、75-79中任一所示;或SEQ ID NO:4、86-90中任一所示;或SEQ ID NO:5、91-95中任一所示;或SEQ ID NO:6、96-100中任一所示;或与前述序列任一具有至少80%、至少90%、至少95%、至少98%或至少99%的序列同一性。
- 如权利要求5或6中任一项所述的PVRIG/TIGIT结合蛋白,其中所述特异性结合TIGIT的第二抗原结合结构域包含重链可变区(VH)和轻链可变区(VL),其中:所述重链可变区包含分别如SEQ ID NO:121、122和123所示的HCDR1、HCDR2和HCDR3,所述轻链可变区包含分别如SEQ ID NO:124、125和126所示的LCDR1、LCDR2和LCDR3;或所述重链可变区包含分别如SEQ ID NO:115、116和117所示的HCDR1、HCDR2和HCDR3,所述轻链可变区包含分别如SEQ ID NO:118、119和120所示的LCDR1、LCDR2和LCDR3;或所述重链可变区包含分别如SEQ ID NO:127、128和129所示的HCDR1、HCDR2和HCDR3,所述轻链可变区包含分别如SEQ ID NO:130、131和132所示的LCDR1、LCDR2和LCDR3;或所述重链可变区包含分别如SEQ ID NO:133、134和135所示的HCDR1、HCDR2和HCDR3,所述轻链可变区包含分别如SEQ ID NO:136、137和138所示的LCDR1、LCDR2和LCDR3;或所述重链可变区包含分别如SEQ ID NO:139、140和141所示的HCDR1、HCDR2和HCDR3,所述轻链可变区包含分别如SEQ ID NO:142、143和144所示的LCDR1、LCDR2和LCDR3。
- 如权利要求7所述的PVRIG/TIGIT结合蛋白,其中,所述特异性结合TIGIT的第二抗原结合结构域的重链可变区包含如SEQ ID NO:145-147中任一所示或与之具有至少90%、至少95%、至少98%、至少99%序列同一性的氨基酸序列,轻链可变区包含如SEQ ID NO:148-149中任一所示或与之具有至少90%、至少95%、至少98%、至少99%序列同一性的氨基酸序列。
- 如权利要求8所述的PVRIG/TIGIT结合蛋白,其中,所述特异性结合TIGIT的第二抗原结合结构域包含全长重链(HC)和全长轻链(LC);优选地,所述全长重链为IgG1或IgG4同种型,所述全长轻链为Kappa同种型;更优选地,所述重链序列为SEQ ID NO:102所示或与之具有至少90%序列同一性,所述轻链序列为SEQ ID NO:103所示或与之具有至少90%序列同一性。
- 如权利要求5-9中任一项所述的PVRIG/TIGIT结合蛋白,所述特异性结合TIGIT的第二抗原结合结构域包含重链可变区(VH)和轻链可变区(VL),其中:所述特异性结合PVRIG的第一抗原结合结构域的免疫球蛋白单一可变结构域位于特异性结合TIGIT的第二抗原结合结构域的重链可变区的N端;所述特异性结合PVRIG的第一抗原结合结构域的免疫球蛋白单一可变结构域位于特异性结合TIGIT的第二抗原结合结构域的重链可变区的C端;所述特异性结合PVRIG的第一抗原结合结构域的免疫球蛋白单一可变结构域位于特异性结合TIGIT的第二抗原结合结构域的轻链可变区的N端;和/或所述特异性结合PVRIG的第一抗原结合结构域的免疫球蛋白单一可变结构域位于特异性结合TIGIT的第二抗原结合结构域的轻链可变区的C端。
- 如权利要求10所述的PVRIG/TIGIT结合蛋白,其中,特异性结合PVRIG的第一抗原结合结构域的免疫球蛋白单一可变结构域与特异性结合TIGIT的第二抗原结合结构域直接或通过连接子相连接;优选地,所述连接子为具有如(G 4S) x所示的氨基酸序列,其中,x独立地选自1-20的整数;更优选地,所述连接子为(G 4S) 2、(G 4S) 3所示的氨基酸序列。
- 如权利要求5-11中任一项所述的PVRIG/TIGIT结合蛋白,其包含第一多肽链和第二多肽链,其中:所述第一多肽链包含如SEQ ID NO:108-112和114中任一所示的氨基酸序列,所述第二多肽链包含如SEQ ID NO:103所示的氨基酸序列;或者所述第一多肽链包含如SEQ ID NO:104或105所示的氨基酸序列,所述第二多肽链包含如SEQ ID NO:103所示的氨基酸序列;或者所述第一多肽链包含如SEQ ID NO:102所示的氨基酸序列,所述第二多肽链包含如SEQ ID NO:106或107所示的氨基酸序列。
- 抗PVRIG抗体或其抗原结合片段,其含有权利要求1-3或5-6中任一项所述的免疫球蛋白单一可变结构域;优选地,其还包含权利要求7中所述的特异性结合TIGIT的第二抗原结合结构域。
- 多核苷酸,其编码权利要求1-4任一项所述的PVRIG结合蛋白、权利要求5-12任一项所述的PVRIG/TIGIT结合蛋白或权利要求13所述的抗PVRIG抗体或其抗原结合片段。
- 宿主细胞,其包含权利要求14所述的多核苷酸。
- 制备PVRIG结合蛋白、PVRIG/TIGIT结合蛋白、或抗PVRIG抗体或其抗原结合片段的方法,包括:在权利要求15所述的宿主细胞中表达权利要求14所述的多核苷酸,以及从所述宿主细胞中分离表达的PVRIG结合蛋白、PVRIG/TIGIT结合蛋白或抗PVRIG抗体或其抗原结合片段。
- 药物组合物,其含有权利要求1-4任一项所述的PVRIG结合蛋白、权利要求5-12任一项所述的PVRIG/TIGIT结合蛋白、或权利要求13所述的抗PVRIG抗体或其抗原结合片段,以及,可药用的赋形剂、稀释剂或载体。
- 治疗疾病或延缓疾病进展的方法,包括:向受试者施用治疗或延缓疾病有效量的权利要求1-4任一项所述的PVRIG结合蛋白、权利要求5-12任一项所述的PVRIG/TIGIT结合蛋白、或权利要求13所述的抗PVRIG抗体或其抗原结合片段、权利要求14所述的多核苷酸、或权利要求17所述的药物组合物,或其任意组合,优选地,所述疾病为增殖性疾病;更有选地,所述增殖性疾病为癌症;更优选地,所述癌症选自肺癌、前列腺癌、乳腺癌、头颈部癌、食管癌、胃癌、结肠癌、结直肠癌、膀胱癌、宫颈癌、子宫癌、卵巢癌、肝癌、黑色素瘤、肾癌、鳞状细胞癌、血液系统癌症或者任何特征在于不受控细胞生长的其它疾病或病症。
- 活化NK细胞、γδT细胞和/或Th1细胞的方法,包含向有需要的受试者施用有效量的权利要求1-4任一项所述的PVRIG结合蛋白、权利要求5-12任一项所述的PVRIG/TIGIT结合蛋白、或权利要求13所述的抗PVRIG抗体或其抗原结合片段、权利要求14所述的多核苷酸、或权利要求17所述的药物组合物或其任意组合。
- 增加受试者体内的干扰素-γ产生和/或促炎性细胞因子分泌的方法,包含向有需要的受试者施用有效量的权利要求1-4任一项所述的PVRIG结合蛋白、权利要求5-12任一项所述的PVRIG/TIGIT结合蛋白、或权利要求13所述的抗PVRIG抗体或其抗原结合片段、权利要求14所述的多核苷酸、或权利要求17所述的药物组合物或其任意组合。
- 根据权利要求1-4任一项所述的PVRIG结合蛋白、权利要求5-12任一项所述的PVRIG/TIGIT结合蛋白、或权利要求13所述的抗PVRIG抗体或其抗原结合片段、权利要求14所述的多核苷酸、或权利要求17所述的药物组合物,用于治疗或延缓疾病,优选地,所述疾病为增殖性疾病;更有选地,所述增殖性疾病为癌症;更优选地,所述癌症选自肺癌、前列腺癌、乳腺癌、头颈部癌、食管癌、胃癌、结肠癌、结直肠癌、膀胱癌、宫颈癌、子宫癌、卵巢癌、肝癌、黑色素瘤、肾癌、鳞状细胞癌、血液系统癌症或者任何特征在于不受控细胞生长的其它疾病或病症。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022551318A JP2023516936A (ja) | 2020-03-13 | 2021-03-12 | Pvrig結合タンパク質及びその医薬用途 |
KR1020227034534A KR20220154140A (ko) | 2020-03-13 | 2021-03-12 | Pvrig 결합 단백질 및 이의 의학적 용도 |
CN202180010585.3A CN115003333A (zh) | 2020-03-13 | 2021-03-12 | Pvrig结合蛋白及其医药用途 |
EP21768888.6A EP4119162A4 (en) | 2020-03-13 | 2021-03-12 | PVRIG-BINDING PROTEIN AND ITS MEDICAL USES |
US17/905,694 US20240043530A1 (en) | 2020-03-13 | 2021-03-12 | PVRIG Binding Protein And Its Medical Uses |
CA3170025A CA3170025A1 (en) | 2020-03-13 | 2021-03-12 | Pvrig binding protein and its medical uses |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010174835 | 2020-03-13 | ||
CN202010174835.4 | 2020-03-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021180205A1 true WO2021180205A1 (zh) | 2021-09-16 |
Family
ID=77672140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/080470 WO2021180205A1 (zh) | 2020-03-13 | 2021-03-12 | Pvrig结合蛋白及其医药用途 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20240043530A1 (zh) |
EP (1) | EP4119162A4 (zh) |
JP (1) | JP2023516936A (zh) |
KR (1) | KR20220154140A (zh) |
CN (1) | CN115003333A (zh) |
CA (1) | CA3170025A1 (zh) |
TW (1) | TW202144417A (zh) |
WO (1) | WO2021180205A1 (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023040935A1 (zh) * | 2021-09-15 | 2023-03-23 | 江苏恒瑞医药股份有限公司 | 一种含抗pvrig/tigit双特异性抗体的药物组合物 |
WO2023040940A1 (zh) * | 2021-09-15 | 2023-03-23 | 江苏恒瑞医药股份有限公司 | Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症 |
WO2023186063A1 (zh) * | 2022-04-02 | 2023-10-05 | 普米斯生物技术(珠海)有限公司 | 抗pvrig抗体、其药物组合物及用途 |
WO2023186081A1 (zh) * | 2022-04-02 | 2023-10-05 | 普米斯生物技术(珠海)有限公司 | 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途 |
WO2023236980A1 (zh) * | 2022-06-08 | 2023-12-14 | 山东先声生物制药有限公司 | 一种pvrig/tigit双特异性抗体药物组合物及其用途 |
WO2024027824A1 (zh) * | 2022-08-05 | 2024-02-08 | 上海君实生物医药科技股份有限公司 | 抗cd112r抗体药物组合物及其用途 |
WO2024032700A1 (en) * | 2022-08-10 | 2024-02-15 | Beigene, Ltd. | Anti-pvrig antibodies and methods of use |
WO2024046245A1 (zh) * | 2022-08-31 | 2024-03-07 | 石药集团巨石生物制药有限公司 | 抗pvrig抗体及其应用 |
WO2024098980A1 (en) * | 2022-11-10 | 2024-05-16 | Huahui Health Ltd. | Anti-cd112r antibodies and use thereof |
Citations (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
WO1994004678A1 (en) | 1992-08-21 | 1994-03-03 | Casterman Cecile | Immunoglobulins devoid of light chains |
WO1994013804A1 (en) | 1992-12-04 | 1994-06-23 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
US5624821A (en) | 1987-03-18 | 1997-04-29 | Scotgen Biopharmaceuticals Incorporated | Antibodies with altered effector functions |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
WO2003048731A2 (en) | 2001-12-03 | 2003-06-12 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7371826B2 (en) | 1999-01-15 | 2008-05-13 | Genentech, Inc. | Polypeptide variants with altered effector function |
WO2009126688A2 (en) | 2008-04-09 | 2009-10-15 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
WO2014089113A1 (en) | 2012-12-03 | 2014-06-12 | Bristol-Myers Squibb Company | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
US8883973B2 (en) | 2004-11-12 | 2014-11-11 | Xencor, Inc. | Fc variants with altered binding to FcRn |
WO2015009856A2 (en) | 2013-07-16 | 2015-01-22 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
WO2015143343A2 (en) | 2014-03-21 | 2015-09-24 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring |
WO2015174439A1 (ja) | 2014-05-13 | 2015-11-19 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子 |
WO2016028656A1 (en) | 2014-08-19 | 2016-02-25 | Merck Sharp & Dohme Corp. | Anti-tigit antibodies |
US20160176963A1 (en) | 2014-12-23 | 2016-06-23 | Bristol-Myers Squibb Company | Antibodies to tigit |
WO2016134333A1 (en) | 2015-02-19 | 2016-08-25 | Compugen Ltd. | Anti-pvrig antibodies and methods of use |
WO2016134335A9 (en) * | 2015-02-19 | 2016-10-13 | Compugen Ltd. | Pvrig polypeptides and methods of treatment |
WO2017030823A2 (en) | 2015-08-14 | 2017-02-23 | Merck Sharp & Dohme Corp. | Anti-tigit antibodies |
WO2017053748A2 (en) | 2015-09-25 | 2017-03-30 | Genentech, Inc. | Anti-tigit antibodies and methods of use |
WO2017066714A1 (en) * | 2015-10-16 | 2017-04-20 | Compugen Ltd. | Anti-vsig1 antibodies and drug conjugates |
WO2019062832A1 (zh) | 2017-09-29 | 2019-04-04 | 江苏恒瑞医药股份有限公司 | Tigit抗体、其抗原结合片段及医药用途 |
CN110088132A (zh) * | 2016-08-17 | 2019-08-02 | 康姆普根有限公司 | 抗tigit抗体,抗pvrig抗体及其组合 |
WO2019232484A1 (en) | 2018-06-01 | 2019-12-05 | Compugen Ltd | Anti-pvrig/anti-tigit bispecific antibodies and methods of use |
CN110799213A (zh) * | 2017-06-01 | 2020-02-14 | 康姆普根有限公司 | 三联组合抗体疗法 |
-
2021
- 2021-03-12 CA CA3170025A patent/CA3170025A1/en active Pending
- 2021-03-12 TW TW110108958A patent/TW202144417A/zh unknown
- 2021-03-12 US US17/905,694 patent/US20240043530A1/en active Pending
- 2021-03-12 CN CN202180010585.3A patent/CN115003333A/zh active Pending
- 2021-03-12 KR KR1020227034534A patent/KR20220154140A/ko active Search and Examination
- 2021-03-12 WO PCT/CN2021/080470 patent/WO2021180205A1/zh active Application Filing
- 2021-03-12 EP EP21768888.6A patent/EP4119162A4/en active Pending
- 2021-03-12 JP JP2022551318A patent/JP2023516936A/ja active Pending
Patent Citations (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
US5624821A (en) | 1987-03-18 | 1997-04-29 | Scotgen Biopharmaceuticals Incorporated | Antibodies with altered effector functions |
US5648260A (en) | 1987-03-18 | 1997-07-15 | Scotgen Biopharmaceuticals Incorporated | DNA encoding antibodies with altered effector functions |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
WO1994004678A1 (en) | 1992-08-21 | 1994-03-03 | Casterman Cecile | Immunoglobulins devoid of light chains |
WO1994013804A1 (en) | 1992-12-04 | 1994-06-23 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7371826B2 (en) | 1999-01-15 | 2008-05-13 | Genentech, Inc. | Polypeptide variants with altered effector function |
WO2003048731A2 (en) | 2001-12-03 | 2003-06-12 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
US8883973B2 (en) | 2004-11-12 | 2014-11-11 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US20130251720A1 (en) | 2008-04-09 | 2013-09-26 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
WO2009126688A2 (en) | 2008-04-09 | 2009-10-15 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
WO2014089113A1 (en) | 2012-12-03 | 2014-06-12 | Bristol-Myers Squibb Company | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
WO2015009856A2 (en) | 2013-07-16 | 2015-01-22 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
WO2015143343A2 (en) | 2014-03-21 | 2015-09-24 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring |
WO2015174439A1 (ja) | 2014-05-13 | 2015-11-19 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子 |
WO2016028656A1 (en) | 2014-08-19 | 2016-02-25 | Merck Sharp & Dohme Corp. | Anti-tigit antibodies |
WO2016106302A1 (en) | 2014-12-23 | 2016-06-30 | Bristol-Myers Squibb Company | Antibodies to tigit |
US20160176963A1 (en) | 2014-12-23 | 2016-06-23 | Bristol-Myers Squibb Company | Antibodies to tigit |
WO2016134333A1 (en) | 2015-02-19 | 2016-08-25 | Compugen Ltd. | Anti-pvrig antibodies and methods of use |
WO2016134335A9 (en) * | 2015-02-19 | 2016-10-13 | Compugen Ltd. | Pvrig polypeptides and methods of treatment |
CN107580500A (zh) * | 2015-02-19 | 2018-01-12 | 康姆普根有限公司 | 抗pvrig抗体和使用方法 |
WO2017030823A2 (en) | 2015-08-14 | 2017-02-23 | Merck Sharp & Dohme Corp. | Anti-tigit antibodies |
WO2017053748A2 (en) | 2015-09-25 | 2017-03-30 | Genentech, Inc. | Anti-tigit antibodies and methods of use |
WO2017066714A1 (en) * | 2015-10-16 | 2017-04-20 | Compugen Ltd. | Anti-vsig1 antibodies and drug conjugates |
CN110088132A (zh) * | 2016-08-17 | 2019-08-02 | 康姆普根有限公司 | 抗tigit抗体,抗pvrig抗体及其组合 |
CN110799213A (zh) * | 2017-06-01 | 2020-02-14 | 康姆普根有限公司 | 三联组合抗体疗法 |
WO2019062832A1 (zh) | 2017-09-29 | 2019-04-04 | 江苏恒瑞医药股份有限公司 | Tigit抗体、其抗原结合片段及医药用途 |
WO2019232484A1 (en) | 2018-06-01 | 2019-12-05 | Compugen Ltd | Anti-pvrig/anti-tigit bispecific antibodies and methods of use |
Non-Patent Citations (39)
Title |
---|
"GenBank", Database accession no. AAI01289.1 |
BARBAS ET AL., PROC. NAT. ACAD. SCI, USA, vol. 91, pages 3809 - 3813 |
BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426 |
CACECI ET AL., BYTE, vol. 9, 1984, pages 340 - 362 |
CHAN CACARTER PJ, NATURE REV IMMUNOL, vol. 10, 2010, pages 301 - 316 |
CHOTHIA ET AL., J. MOL. BIOL., vol. 196, 1986, pages 901 - 17 |
CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 877 - 83 |
DEFFAR ET AL., AFRICAN JOURNAL OF BIOTECHNOLOGY, vol. 8, no. 12, 17 June 2009 (2009-06-17), pages 2645 - 2652 |
ESOHE E.IDUSOGIE ET AL., J IMMUUNOL, vol. 164, 2000, pages 4178 - 4184 |
HAMERS-CASTERMAN CATARHOUCH TMUYLDERMANS SROBINSON GHAMERS CSONGA EBBENDAHMAN NHAMERS R.: "Naturally occurring antibodies devoid of light chains", NATURE, vol. 363, 1993, pages 446 - 448, XP002535892, DOI: 10.1038/363446a0 |
HAWKINS ET AL., J.MOI.BIOL., vol. 226, no. 3, 1992, pages 889896 |
HOLLIGER ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 90, 1993, pages 6444 - 6448 |
HUSTON ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 85, 1988, pages 5879 - 5883 |
J. BIOL. CHEM, vol. 243, 1968, pages 3558 |
JACKSON ET AL., J. IMMUNOL., vol. 154, no. 7, 1995, pages 3310 - 9 |
JAGANNATHAN SUJATHA, BRADLEY ROBERT K.: "Translational Plasticity Facilitates the Accumulation of Nonsense Genetic Variants in the Human Population", GENOME RESEARCH, vol. 26, no. 12, 31 December 2016 (2016-12-31), US, pages 1639 - 1650, XP055846589, ISSN: 1088-9051, DOI: 10.1101/gr.205070.116 * |
JOHNSONWU, NUCLEIC ACIDS RES., vol. 28, 2000, pages 214 - 8 |
KABAT, E. A. ET AL.: "Sequences of Proteins of Immunological Interest", 1991 |
KS JOHNSONRE HAWKINS: "Epitope Mapping Protocols in Methods in Molecular Biology", vol. 66, 1996, OXFORD UNIVERSITY PRESS |
LEONARD G PRESTA, CURRENT OPINION IN IMMUNOLOGY, vol. 20, 2008, pages 460 - 470 |
LI ET AL., J BIOL CHEM., vol. 287, 2012, pages 13713 - 13721 |
MACCALLUM ET AL., J. MOL. BIOL., vol. 5, 1996, pages 732 - 45 |
MAKABE ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 283, 2008, pages 1156 - 1166 |
MARKS ET AL., BIOTECHNOLOGY, vol. 10, 1992, pages 779 - 783 |
MARTIN ET AL., PROC NATL ACAD SCI (USA, vol. 86, 1989, pages 9268 - 9272 |
PAUL R.HINTON ET AL., J IMMUNOL, vol. 176, 2006, pages 346 - 356 |
R REMINGTON: "The Science and Practice of Pharmacy", 2000, MACK PUBLISHING CO. |
R. VAN DER LINDEN ET AL., JOURNAL OF IMMUNOLOGICAL METHODS, vol. 240, 2000, pages 185 - 195 |
RAPHAEL A.CLYNES ET AL., NATURE MEDICINE, vol. 6, no. 4, 2000, pages 443 - 446 |
SAMBROOK ET AL.: "Current Protocols in Molecular Biology", COLD SPRING HARBOR LABORATORY PRESS |
SAMUDRALA ET AL.: "Ab Initio Protein Structure Prediction Using a Combined Hierarchical Approach", PROTEINS, STRUCTURE, FUNCTION AND GENETICS, vol. 3, 1999, pages 194 - 198, XP001146416 |
SANCHEZ-CORREA BEATRIZ, VALHONDO ISABEL, HASSOUNEH FAKHRI, LOPEZ-SEJAS NELSON, PERA ALEJANDRA, BERGUA JUAN M., ARCOS MARIA JOSE, B: "DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy", CANCER, vol. 11, no. 6, 877, 23 June 2019 (2019-06-23), pages 1 - 15, XP055846585, DOI: 10.3390/cancers11060877 * |
See also references of EP4119162A4 |
SHIELDS, R. L. ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 6591 - 6604 |
SHIER ET AL., GENE, vol. 169, pages 147 - 155 |
TOMLINSON ET AL., METHODS ENZYMOL., vol. 326, 2000, pages 461 - 479 |
WATSON ET AL.: "Molecular Biology of the Gene", 1987, THE BENJAMIN/CUMMINGS PUB. CO., pages: 224 |
WONGLOHMAN, PNAS, vol. 90, 1993, pages 5428 - 5432 |
YELTON ET AL., IMMUNOL, vol. 155, 1995, pages 1994 - 2004 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023040935A1 (zh) * | 2021-09-15 | 2023-03-23 | 江苏恒瑞医药股份有限公司 | 一种含抗pvrig/tigit双特异性抗体的药物组合物 |
WO2023040940A1 (zh) * | 2021-09-15 | 2023-03-23 | 江苏恒瑞医药股份有限公司 | Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症 |
WO2023186063A1 (zh) * | 2022-04-02 | 2023-10-05 | 普米斯生物技术(珠海)有限公司 | 抗pvrig抗体、其药物组合物及用途 |
WO2023186081A1 (zh) * | 2022-04-02 | 2023-10-05 | 普米斯生物技术(珠海)有限公司 | 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途 |
WO2023236980A1 (zh) * | 2022-06-08 | 2023-12-14 | 山东先声生物制药有限公司 | 一种pvrig/tigit双特异性抗体药物组合物及其用途 |
WO2024027824A1 (zh) * | 2022-08-05 | 2024-02-08 | 上海君实生物医药科技股份有限公司 | 抗cd112r抗体药物组合物及其用途 |
WO2024032700A1 (en) * | 2022-08-10 | 2024-02-15 | Beigene, Ltd. | Anti-pvrig antibodies and methods of use |
WO2024046245A1 (zh) * | 2022-08-31 | 2024-03-07 | 石药集团巨石生物制药有限公司 | 抗pvrig抗体及其应用 |
WO2024098980A1 (en) * | 2022-11-10 | 2024-05-16 | Huahui Health Ltd. | Anti-cd112r antibodies and use thereof |
Also Published As
Publication number | Publication date |
---|---|
TW202144417A (zh) | 2021-12-01 |
JP2023516936A (ja) | 2023-04-21 |
EP4119162A1 (en) | 2023-01-18 |
CA3170025A1 (en) | 2021-09-16 |
US20240043530A1 (en) | 2024-02-08 |
CN115003333A (zh) | 2022-09-02 |
EP4119162A4 (en) | 2023-08-23 |
KR20220154140A (ko) | 2022-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021180205A1 (zh) | Pvrig结合蛋白及其医药用途 | |
ES2746805T3 (es) | Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo | |
EP3936526A1 (en) | Bifunctional fusion protein and pharmaceutical use thereof | |
EP3632932A1 (en) | Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof | |
CN112969714B (zh) | 抗cd40抗体、其抗原结合片段及其医药用途 | |
JP2022502076A (ja) | 抗tnfr2抗体およびその使用 | |
KR20210049792A (ko) | 인간 il-4r 결합 항체, 이의 항원 결합 단편, 및 이의 의학적 용도 | |
BR112020014848A2 (pt) | Anticorpo anti-4-1bb, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo | |
TWI836070B (zh) | 抗trop-2抗體、其抗原結合片段及其醫藥用途 | |
JP2022502417A (ja) | 抗ox40抗体、その抗原結合フラグメント、および医薬用途 | |
WO2023274201A1 (zh) | 抗cd40抗体、其抗原结合片段及医药用途 | |
JP2024514277A (ja) | 単一ドメインpd-l1抗体 | |
WO2021213245A1 (zh) | 抗体或其抗原结合片段、其制备方法及医药用途 | |
TW201904999A (zh) | 抗gitr抗體、其抗原結合片段及其醫藥用途 | |
KR20220030937A (ko) | 항체 및 사용 방법 | |
WO2023040945A1 (zh) | 特异性结合pd-1的蛋白及其医药用途 | |
WO2023040935A1 (zh) | 一种含抗pvrig/tigit双特异性抗体的药物组合物 | |
WO2021164722A1 (zh) | 抗il-2抗体、其抗原结合片段及其医药用途 | |
WO2022078490A1 (zh) | 抗erbb3抗体或其抗原结合片段及其医药用途 | |
JP7014783B2 (ja) | 抗cd27抗体、その抗原結合性フラグメント、およびそのものの医学的使用 | |
WO2023098785A1 (zh) | 抗4-1bb抗体及其用途 | |
WO2022166846A1 (zh) | 抗tnfr2抗体及其用途 | |
WO2022078424A1 (zh) | 抗trop-2抗体、其抗原结合片段或其突变体、及其医药用途 | |
WO2022144025A1 (zh) | 一种抗erbb3受体的抗体或其抗原结合片段及其医药用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21768888 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3170025 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022551318 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 17905694 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 20227034534 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2021768888 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2021768888 Country of ref document: EP Effective date: 20221013 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |